Changes in Burden of Cardiovascular Disease Following Hypothetical Reductions in Adiposity by Gellert, Shannon
 CHANGES IN BURDEN OF CARDIOVASCULAR DISEASE FOLLOWING HYPOTHETICAL 
REDUCTIONS IN ADIPOSITY  
Shannon Kapuaolaokalaniākea Gellert 
A dissertation submitted to the faculty at the University of North Carolina at 
Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of 















Shannon Kapuaolaokalaniākea Gellert: Changes in Burden of Cardiovascular 
Disease Following Hypothetical Reductions in Adiposity.  
(Under the direction of Gerardo Heiss) 
Cardiovascular diseases (CVD) such as peripheral artery disease (PAD) and 
coronary heart disease (CHD) are prominent causes of disability and death. PAD is 
a limb and life-threatening condition affecting 8.5 million U.S adults and CHD is the 
leading cause of death in the U.S. Risk factors for these CVD include hypertension 
and diabetes, which may lie on the causal pathway from adiposity to PAD and CHD. 
Therefore, adiposity may represent a modifiable upstream risk factor for PAD and 
CHD. Given the temporal increase in adiposity in the U.S. and the need to address 
the adverse health effects of adiposity at the population level, this doctoral research 
aimed to estimate the impact of hypothetical population reductions in adiposity on 
the incidence of PAD and CHD.  
Our study population included over 13,000 Atherosclerosis Risk in 
Communities participants examined from 1987 to 2001 at 4 triennial study visits 
during which exposure and covariate information were ascertained. Incident PAD 
and CHD events were identified from cohort follow-up and active health event 
surveillance. The parametric g-formula was used to estimate the risk difference of 
PAD and CHD following a hypothetical 5% reduction in body mass index (BMI) or 
waist circumference (WC) relative to the natural course of the BMI or WC trajectory, 
to a minimum BMI of 24 kg/m2 or WC of 88 cm.
iv 
Participants with incident PAD or CHD were older at baseline, and more likely 
to be male, of white race, have less than a high school education, smoke, have 
diabetes, and have hypertension compared to those without incident PAD or CHD. 
We estimated a small risk difference for PAD [-0.17%, 95% confidence interval (CI): 
-0.38, 0.13%] following a 5% reduction in BMI. The estimated risk difference for CHD 
was -0.56% (95% CI: -0.96, -0.14%) following a 5% reduction in BMI, and -0.96% 
(95% CI: -1.44, 0.48%) following a 5% reduction in WC. 
 If replicated in other populations, these results can inform prevention-oriented 
research into the health effects of dynamic population distributions of adiposity 
measures. 
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CHAPTER 1: SPECIFIC AIMS 
1.1 Proposed specific aims  
The initially proposed three aims of this dissertation (Appendix) were to: Aim 
1) quantify the change in three specified cardio-metabolic risk factors – systolic 
blood pressure (SBP), fasting plasma glucose (FPG) and low density lipoprotein 
cholesterol (LDL-C) associated with decrements in adiposity; Aim 2) estimate the 
individual and joint impact of decrements in adiposity on three specified cardio-
metabolic risk factors and apply these estimates to our study population; and Aim 3) 
estimate the change in longevity, disability and incidence of diabetes and coronary 
heart disease (CHD) predicted from small changes in the population distribution of 
adiposity.   
On advice from my dissertation committee, Aim 1 was built on a systematic 
review developed in support of the clinical guidelines on the identification and 
treatment of overweight and obesity in adults1,2, to quantify the changes in body 
mass index (BMI) and the changes in each of the cardio-metabolic risk factors. A 
further recommendation from the dissertation committee was to limit the scope of the 
doctoral research to two of the cardio-metabolic risk factors: SBP and FPG. This 
restriction still allowed us to implement the study aims as proposed given the 
prominent role of these two cardio-metabolic impairments in the risk for the CVD 
conditions selected for this study. 
1 
Aims 2 and 3 were modified to estimate the effect of a modest hypothetical 
yearly reduction (5%) in adiposity - BMI for Manuscript 1 (MS#1) and BMI and WC 
for Manuscript 2 (MS#2) on cumulative incidence of peripheral artery disease (PAD) 
(MS#1) and CHD (MS#2).  
1.2 Specific aims after modifications: 
Aim 1. Characterize the cross-sectional association between BMI and two 
specified cardio-metabolic risk factors - SBP and FPG in the ARIC cohort. Compare 
the effect estimates of the decrement in BMI on SBP and FPG derived from the 
human experimental literature to their observational equivalent in the ARIC cohort. 
Hypotheses: There will be a monotonic linear relationship between BMI and SBP, 
and between BMI and FPG. These relationships will not have evidence of a 
threshold over the range of the adiposity distribution included in our analysis 
(BMI=24-40 kg/m2). The association between BMI and SBP and FPG will be 
comparable in shape and magnitude across race, sex and birth cohort. The 
association between BMI and SBP and FPG in the ARIC cohort will be comparable 
in magnitude to the association found in the human-experimental data, after 
adjustment for confounders.  
Aim 2. Estimate the change in 12-year cumulative incidence of peripheral 
artery disease (PAD) following a hypothetical 5% yearly body mass index (BMI) 
reduction down to a BMI of 24 kg/m2 for all individuals under 65 years of age with a 
BMI> 24 kg. Hypothesis: Reducing BMI by 5% each year reduces the cumulative 
incidence of PAD.  
Aim 3. Estimate the change in 12-year cumulative incidence of coronary 
heart disease (CHD) following a hypothetical 5% yearly body mass index (BMI) 
2 
reduction down to a BMI of 24 kg/m2 for all individuals under 65 years of age with a 
BMI> 24 kg. Hypothesis: Reducing BMI by 5% each year reduces the cumulative 
incidence of CHD.  
Aim 4. Estimate the change in 12-year cumulative incidence of coronary 
heart disease (CHD) following a hypothetical 5% yearly waist circumference (WC) 
reduction down to a WC of 88 cm for all individuals under 65 years of age with a 





1. Pi-Sunyer FX. NHLBI Obesity Education Initiative Expert Panel on the 
identification, evaluation, and treatment of overweight and obesity in adults-
The evidence report. Obesity Research. 1998;6:51S-209S. 
 
2. Jensen MDMD. 2013 AHA/ACC/TOS guideline for the management of 
overweight and obesity in adults: a report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines 
and The Obesity Society. Journal of the American College of 
Cardiology.63(25 pt b):2985-3023. 
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CHAPTER 2: BACKGROUND AND SIGNIFICANCE 
This background section summarizes the literature review conducted to address the 
overall goal of my doctoral work.  
2.1 Burden of cardiovascular disease  
2.1.1 Global mortality 
Cardiovascular disease is a major global public health burden as a result of 
its high mortality and morbidity1. In the twenty years spanning the 1990 Global 
Burden of Disease study (GBD) and the 2010 GBD, ischemic heart disease and 
cerebrovascular disease remained the top two leading causes of death in North 
America and even worldwide2. In addition, a study on projections of global mortality 
from 2002 to 2030 predicted that total cardiovascular-related deaths would increase 
globally from 16.7 million in 2002 to 23.3 million in 20303. Mortality data have 
traditionally been used for identifying a population’s health problems4. However, 
other assessments of population health that were developed in the GBD studies are 
more informative as the global disease burden shifts away from premature death to 
years lived with disability and from communicable to non-communicable diseases5.   
2.1.2 DALYs 
The GBD studies measured disease burden using disability adjusted life 
years (DALYs), which indicate the number of healthy years of life lost5. Somewhat 
similar to the findings reported for the leading causes of death, ischemic heart 
disease and cerebrovascular disease were respectively the 1st and 3rd leading
5 
causes of DALYs globally2. Although ischemic heart disease is ranked first as the 
leading cause of DALYs in North America, cerebrovascular disease is ranked 7th, 
preceded by other conditions such as lung cancer and chronic obstructive 
pulmonary disorder (COPD). Furthermore, ischemic heart disease and 
cerebrovascular disease are expected to remain the top two leading causes of death 
and the 3rd and 6th leading causes of DALYs in the world in 20303. Although CVD is 
a leading cause of death and DALYs among all populations, CVD disproportionately 
affects minority populations4,6,7.     
2.1.3 CVD burden in US minority populations 
Chronic diseases, to a large degree CVD, are prominent causes of disability 
and premature death in U.S. minority populations4,6,7. African Americans/Blacks had 
more than twice the age-adjusted death rate in 2010 than whites and more than 
twice the age-adjusted estimates of years of potential life lost (YPLL) from diseases 
of the heart compared to whites8. Prevalence of risk factors associated with CVD 
may contribute to the health disparities seen for minorities9.       
Minorities, specifically African Americans are less likely than whites to have 
optimal cardiovascular health profiles measured by levels of cardiovascular risk 
factors, including body mass index (BMI), blood pressure, total cholesterol and 
glucose, thus emphasizing the need to address these health disparities9. As with 
other chronic diseases, CVD represents the downstream outcome of conditions that 
originate early in life and are mediated by well-established behavioral, metabolic and 
environmental risk factors. Adiposity is one of these risk factors and has a well-
documented association with several cardio-metabolic risk factors10-14.     
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2.2 Associations between adiposity and cardio-metabolic risk factors 
Categorical definitions of normal weight, overweight and obesity are often 
used to describe the associations between adiposity and cardio-metabolic risk 
factors and CVD. Use of these categories is common in clinical settings when 
establishing guidelines for diagnosis and treatment is the goal15,16. Several studies 
across the world have documented that overweight and obesity are well-established 
risk factors for CVD and CVD risk factors10,17-28.   
Due to the rising prevalence of overweight and obesity, an examination of the 
scientific evidence on the effects of weight loss on several health factors was 
conducted by the Expert Panel on the Identification, Evaluation, and Treatment of 
Overweight and Obesity in Adults (EPIETOA)15. The EPIETOA was comprised of the 
National Heart, Lung and Blood Institute’s (NHLBI) Obesity Education Initiative and 
the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This 
panel conducted a systematic review of the literature combining evidence from 394 
randomized controlled trials (RCTs). They concluded that all overweight adults, body 
mass index (BMI) >25, are at risk for developing the associated morbidities and 
diseases such as hypertension, high blood cholesterol, type 2 diabetes, and 
coronary heart disease (CHD). This risk is especially high in minority groups, low 
socioeconomic status (SES) groups, and in those who have less education given 
their relatively high prevalence of overweight and obesity compared to non-minority, 
higher SES and higher education groups29. Recommendations for the treatment of 
overweight and obesity were based on evidence that weight loss reduces morbidity 
and mortality associated with cardio-metabolic risk factors. The EPIETOA’s 
systematic review includes evidence for the effect of changes in adiposity (measured 
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as BMI) and the three cardio-metabolic risk factors of interest for this dissertation-
systolic blood pressure (SBP), fasting low-density cholesterol (LDL-C) and fasting 
plasma glucose (FPG). The following sections will summarize and expand this 
information.   
2.2.1 Systolic blood pressure (SBP) 
 One aim of the EPIETOA’s systematic review was to evaluate the effect of 
weight loss on blood pressure and hypertension15. Hypertension was defined as a 
SBP > 140 mmHg, diastolic blood pressure > 90 mmHg or taking hypertension 
medication. The panel concluded that there was strong evidence showing the 
association between weight loss and reductions in SBP in hypertensive and non-
hypertensive adults. The inclusion criteria for the systematic review were that the 
study had a time frame from start to finish of at least 4 months and measured weight 
by study personnel and not only self-report. For this aim of the systematic review, 35 
lifestyle RCT articles met their inclusion criteria with 16 articles on a hypertensive 
population and 19 conducted in individuals with normal or high-normal blood 
pressure. Prior evidence of a linear association between BMI and blood pressure 
that was incorporated into the EPIETOA’s systematic review came from a 1987 
meta-analysis conducted by MacMahon et al30.  
 This meta-analysis reported several important findings. One was that a 22 lb 
weight loss was associated with a 7 mmHg reduction in SBP. Another conclusion 
was that the evidence within and across the included RCTs was suggestive of a 
dose response relationship between change in weight and change in SBP. Also, the 
associations between change in weight and change in blood pressure were not 
specific to any age, race or sex group, but the association appeared to be stronger 
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in younger than older adults and in whites than Blacks30. The EPIETOA’s systematic 
review corroborated many of these findings.     
The EPIETOA summarized the evidence from several studies and concluded 
that weight loss produced by lifestyle modification reduces blood pressure. These 
findings are highly relevant for the rationale of this dissertation. The following 
sections provide a summary of the EPIETOA’s systematic review.   
Trials in hypertensive participants 
The Trial of Antihypertensive Interventions and Management (TAIM) was 
conducted in hypertensive patients who were not taking medication for 6 months. A 
mean net weight reduction of 10.4 lbs reduced SBP by 2.8 mmHg, and the effects 
on blood pressure were equivalent to drug therapy among participants who lost 9.9 
lbs or more31. Mean net weight reduction was calculated by taking the change in 
weight from baseline to the end of the study in both intervention and control groups 
separately. Then, this value from the control group was subtracted from that in the 
intervention group to arrive at mean net weight reduction15.   
The Trial of Nonpharmacologic Interventions in the Elderly (TONE) was 
conducted with participants who were 60-80 years old. During this weight loss 
intervention, blood pressure medications were withdrawn. This study’s investigators 
reported that a 9 lb weight loss reduced the occurrence of hypertension, the need for 
resumption of blood pressure medications and occurrence of cardiovascular clinical 
complication. Additionally, blood pressure control was similar among men, women, 
African Americans and whites.   
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The Multiple Risk Factor Intervention Trial (MRFIT) included men at high-risk 
for heart disease of which 30% were classified as hypertensive. Following an 
integrated weight loss intervention, a 2.2 lb weight loss after 6 years was associated 
with a 0.4 mmHg reduction in SBP32.     
Trials in non-hypertensive participants 
 The Trials of Hypertension Prevention (TOHP I and II) were RCTs conducted 
in men, women, whites and African Americans. Both TOHP I and II demonstrated 
that weight loss reduced blood pressure and the incidence of hypertension. A mean 
weight reduction of 10 kg after 18 months was associated with a 7 mmHg reduction 
in systolic blood pressure.   
SBP is one of the cardio-metabolic risk factors associated with adiposity that 
was selected for consideration in this doctoral research. A continuous and graded 
relationship exists between SBP and CVD morbidity and mortality7,33,34. This 
relationship was demonstrated using Framingham data from 1976-1998. The 
residual lifetime risk (lifetime cumulative incidence not adjusted for competing 
causes of mortality) of hypertension for middle-aged and elderly individuals was 
90%35. In addition, the GBD 2010 study reported that elevated blood pressure was 
the leading global disease burden and that the largest proportion of DALYs for 
Ischemic heart disease is from elevated blood pressure36. Elevated blood pressure 
is a major public health concern due to its frequency of occurrence and its 
association with disease and mortality36,37. 
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2.2.2 Low density lipoprotein cholesterol (LDL-C) 
The EPIETOA’s systematic review also concluded that weight loss produced 
by lifestyle modifications improved lipids38. The following summary will focus on LDL-
C as that was of interest for this dissertation. Eight RCTs that studied the effects of 
diet and/or physical activity on lipids are summarized in Table 139-45. For the 8 
studies that reported values for LDL-C, body weight reductions ranged from a loss of 
13% for the intervention group compared to the control group to a gain of 2%. Net 
percent change in LDL-C ranged from a 22% reduction to a 2% gain when 
comparing intervention to control groups.     
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Table 1.Summary of RCTs included in the EPIETOA's systematic review of 





Number, sex, and 
group assignment   
Duration 
(months) 





Dengel, 199539  28 M (I)  
9 -12 -9 
14 M (C) 
Hellenius, 199340 40 M (I)  
6 -2 -3 
39 M (C) 
Simkin-Silverman, 
199541 
253 F (I) 
6 -7 -9 
267 F (C) 
Svendsen, 199442  50 F (I) 
12 weeks -13 -22 
20 F (C) 
Wood, 199143  40 M (I) 
12 
-7 -5 
40 M (C) 
31 F (I)  
-7 -8 
39 F (C) 
Wood, 198844  42 M (I) 
12 -8 -3 42 M (C) 
Diet plus physical activity 
Hellinius, 199340  39 M (I) 
6 -4 -4 39 M (C) 
Physical activity only 





41 M (C) 
42 M high intensity at 
home -1 -1 
41 M (C) 
45 M low intensity 
-4 0 41 M (C) 
34 F high intensity in 
group  
2 -4 34 F (C) 
35 F high intensity home 
0 
3 34 F (C) 
29 F low intensity 
-2 3 34 F (C) 
 
*Adapted from NHLBI 199815 to include only the results for low-density lipoprotein (LDL-C). 
**RCT: randomized controlled trial; EPIETOA: Expert Panel on the Identification Evaluation and 
Treatment of Overweight and Obesity in Adults; (I): Intervention group, (C): control group.  
***Results for LDL-C. ****net %change = difference in percent change between intervention and 
control groups; %change=[(value at the end of the study minus baseline)/value at baseline]. 
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2.2.3 Glucose  
Blood glucose levels were also reduced in diabetics and non-diabetics 
following weight loss38. This section of the systematic review included 9 RCT reports 
that examined lifestyle therapy41,46-53. Five included normoglycemic individuals, 1 
included participants with impaired glucose tolerance, and 3 included patients with 
type 2 diabetes. The five studies among normoglycemic individuals showed that 
weight loss improved fasting glucose along with fasting insulin levels. The three 
RCTs conducted in diabetic patients showed similar results47,51,53. One RCT in 
African Americans showed that a 2.4 kg weight loss decreased hemoglobin A1c 
(HbA1c) by 2.4 percentage units at 6 months in intervention participants compared 
to controls47.   
The systematic review prepared by the EPIETOA provides strong evidence of 
the relationship between weight reduction and the cardio-metabolic risk factors for 
this dissertation. Further examination of the continuous relationships between 
adiposity and cardio-metabolic risk factors through population studies would help to 
further inform programs aimed to describe CVD risk at a population level54. 
2.2.4 Summary of selected randomized controlled trial weight loss studies on 
changes in adiposity and cardio-metabolic risk factors 
One limitation of the information provided in the systematic review prepared 
by the EPIETOA15 was that cardio-metabolic risk factor values were not always 
reported, as categorical definitions of hypertension, diabetes and dyslipidemia are 
sometimes reported. Therefore, we conducted a limited review of randomized 
controlled lifestyle and surgical weight loss interventions, most of which were 
conducted for 12-months and quantified the associations between small to moderate 
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changes in adiposity and cardio-metabolic risk factors55-58. The observed effects of 
changes in adiposity on SBP, fasting LDL-C, and fasting plasma glucose (FPG) are 
summarized in this table. Also included are follow-up measurements made at 6-
months post intervention, including calculations of amount change in cardio-
metabolic risk factors per 1-unit decrease in BMI.   
For SBP, the largest decreases observed per 1-unit change in BMI were 
noted in the commercial diet programs56 - 3.36 mmHg with the Atkins diet, 4 mmHg 
with Weight Watcher’s, and 4.33 mmHg with the Zone diet. The Ornish diet showed 
a reduction in LDL-C of 8.75 mg/dL per 1-unit change in BMI, by far the largest 
compared to the other interventions. While the focuses of these (and similar) studies 
are on individuals, the translation to the population level has not been addressed to 
our knowledge. For this dissertation SBP and FPG were examined as cardio-
metabolic risk factors influenced by adiposity.      
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Table 2. Summary of selected randomized controlled trial weight loss studies that 
examined the effect of changes in adiposity (BMI) on three cardio-metabolic risk 

























6.7 (15%)   
[45.1] 
3 (2%)  
[134] 
26 (21%)  
[121] 
10 (10%)   
[104] 




201058 PA and diet 
3.9 (9%)   
[43.5] 
3.4 (3%)  
[135.4] . 
3.4 (4%)  
[93.7] 
SBP=-0.87      
Glucose=-0.92 
PA and 
delayed diet  
3.1 (7%)   
[43.7] 
1.9 (1%)   
[134.4] . 
1.9 (2%)  
[93.2] 





3.3 (8%)   
[44] 
1.1 (1%)   
[135.2] 
0.01 (0%)  
[57.7] 
0.17 (0%)  
[93.7] 
SBP=-0.33                 
LDL-C=+0.05     
Glucose=-0.93    
Diet and PA  
3.9 (9%)    
[43.8] 
3 (2%)   
[133.4] 
0.09 (0%)  
[57.7] 
0.26 (0%)  
[93.7] 
SBP=-0.77               







3.7 (3%)    
[129] 
2.7 (2%)  
[136] 
7.8 (6%)  
[127] 
SBP=-3.36                 
LDL-C=-2.45    
Glucose=-7.09 
Zone diet 
0.9 (3%)  
[34] 
3.9 (3%)   
[130] 
6.7 (5%)  
[138] 
8.2 (7%)  
[116] 
SBP=-4.33                 





1.2 (3%)  
[35] 
4.8 (4%)   
[133] 
7 (5%)        
[142] 
3.8 (3%)  
[116] 
SBP=-4                      
LDL-C=-5.83         
Glucose=-3.17 
Ornish diet 
1.2 (3%)   
[35] 
0.6 (0%)  
[133] 
10.5 (8%)  
[136] 
5.1 (4%)  
[121] 
SBP=-0.5               
LDL-C=-8.75      
Glucose=-4.25 
*Note: All outcomes here are taken at 6-months from study initiation.  SBP: systolic blood pressure 
(mmHg), FPG (mg/dL), LDL-C: low-density lipoprotein (mg/dL). Goodpaster study did not report 
LDL-C.  PA: physical activity 
2.3 Adiposity  
The adipose organ is one of the largest organs in the body, constituting about 
20% of total body weight54,59. Early work considered the adipose organ as only a 
storage depot for energy molecules (fatty acids) in the body. Further research into 
the pathophysiology of the complex structure and function of adipose tissue 
throughout the body, based on both murine and human models, led to the 
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awareness of an adipose organ with paracrine, autocrine and endocrine functions. 
These functions offer explanations for the associations between adiposity and 
cardio-metabolic risk factors, specifically SBP and FPG.   
2.3.1 Depots of the adipose organ 
The adipose depots have different structural organization and function. The 
two main depots are: 1) visceral that is found around the internal organs and 2) 
subcutaneous that is mostly stored in the buttocks and trunk60. Total body fat is 
made up of approximately 80-90% subcutaneous and only 6-20% visceral adipose 
tissue, with variations explained by sex and individual differences in patterns of 
accumulation61. Although adipose tissue is mainly found in the visceral and 
subcutaneous depots, other adipose depots specific to organ systems include 
pulmonary, periadventitial, perirenal, bone marrow, and epicardial. Several 
epidemiologic studies have reported that accumulation of visceral adipose tissue is 
associated with increased cardiovascular risk and mortality62-65. Mechanisms 
explaining these associations are not completely understood and possibly relate to 
the resistance to insulin action through increased hepatic exposure to free fatty acids 
leading to hyperinsulinemia, glucose intolerance, and hypertriglyceridemia66.             
2.3.2 Distribution of adipose tissue 
The typical distribution of adipose tissue differs in males and females and by 
menopausal status. At comparable levels of adiposity, men and postmenopausal 
women have more visceral relative to subcutaneous adipose tissue, whereas the 
opposite is true for premenopausal women67-69. Sex steroids have been implicated in 
the sexually dimorphic distribution of adipose tissue. In males, this distribution is 
likely regulated by androgens. Testosterone production in men decreases with age, 
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a third by age 70 years old and half by age 80 years old70. Androgens are not as 
apparent in young females since they exist in much smaller quantities, except for 
women with androgen excess. Female sex steroids such as estrogen may promote 
peripheral or lower-body adipose distribution compared to males. When 
concentrations of estrogen decline following menopause, changes in body fat 
distribution from subcutaneous to visceral are observed68,71.   
2.3.3 White and brown adipocytes 
The adipose organ has a fundamental role in the body and shows strong 
associations with cardio-metabolic risk factors72. The adipose organ is primarily 
comprised of adipocytes, but also contains vascular elements, preadipocytes, 
fibroblasts, mast cells, macrophages, nervous system elements, and mesenchymal 
cells61. Adipose tissue is infiltrated with macrophages at a rate that is correlated with 
BMI and adipocyte size. This infiltration is suggested to be associated with insulin 
resistance and obesity61.   
Two main types of adipose tissue are white adipose tissue (WAT) and brown 
adipose tissue (BAT). The main function of WAT is to store high-energy molecules 
(fatty acids) that can supply fuel during intervals between meals. Other more 
recently discovered functions include the production of adipokines (any substance 
released by adipose tissue) that control glucose and lipid metabolism, blood 
coagulation, blood pressure, and steroid hormone modulation, thereby directly 
influencing metabolic function73.  
BAT functions primarily to use fatty acids to produce heat through non-
shivering thermogenesis, which is important for newborns and small mammals61. 
The surface to volume ratio of humans is quite different from that in small mammals, 
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therefore human thermodispersion is much lower than that in small mammals. This 
results in a reduced need for BAT in adult humans. Although newborns have more 
BAT than adults, BAT is significantly reduced in older human adults61. Therefore, the 
focus here will be on the function of WAT. 
2.3.4 Endocrine function of the adipose organ 
Adipokines have a plethora of functions that affect inflammation, blood 
pressure regulation, and glucose and lipid metabolism74. Key adipokines that are 
associated with modification of the cardio-metabolic risk factors – SPG and FPG for 
this dissertation include leptin, interleukin 6 (IL-6), adiponectin, acylation stimulation 
protein (ASP), tumor necrosis factor alpha (TNF-α), monocyte chemoattractant 
protein 1 (MCP-1), plasminogen activator inhibitor (PAI-1), proteins of the renin 
angiostensinogen system (RAS), and visfatin. Many of these adipokines and their 
functions were discovered in the past ten years, and have not been extensively 
described67,72,75. Table 2 provides a summary of these adipokines and their functions 
related to the cardio-metabolic risk factors of interest.   
   Leptin 
There has been extensive investigation of leptin as a metabolic signal of 
energy sufficiency since its discovery in mice in 199476. The name leptin originates 
from the Greek term leptos meaning thin, because leptin decreased body weight and 
fat mass when injected into mice77. Secretion of leptin by adipocytes is in direct 
proportion to adipose tissue mass as well as nutritional status. Secretion of leptin is 
also greater in subcutaneous compared to visceral adipose tissue with higher levels 
being reported in females compared to males67. Leptin has endocrine, paracrine and 
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autocrine actions78 that have numerous functions including metabolic signaling of 
energy sufficiency, enhancement of insulin sensitivity, and increasing blood pressure 
as shown in human models67,72,75.       
 Il-6 
Interleukin-6 (IL-6) is a pro-inflammatory adipokine that is expressed by 
adipocytes and adipose tissue matrix67. The functions of IL-6 include stimulation of 
C-reactive protein (CRP) expression which increases systemic inflammation, impairs 
glucose tolerance and promotes insulin resistance67,75. The expression and 
secretion of IL-6 is two to three times greater in visceral compared to subcutaneous 
adipose tissue.   
Adiponectin  
In contrast to the pro-inflammatory actions of leptin and IL-6, adiponectin has 
an anti-inflammatory action. Other actions of adiponectin include enhancing insulin 
sensitivity, reducing glucose synthesis and oxidation of LDL-C. Higher 
concentrations of adiponectin have been found in subcutaneous compared to 
visceral adipose tissue and in females compared to males67,72,79. 
Acylation stimulating protein (ASP)  
Studies describing the function of ASP are limited but have demonstrated that 
ASP promotes insulin resistance and dyslipidemia67,80. 
Tumor necrosis factor alpha (TNF-α)  
TNF-α is a pro-inflammatory adipokine and has been shown to impair insulin 
signaling67. TNF-α is expressed by adipocytes and stromovascular cells with higher 
concentrations found in subcutaneous compared to visceral adipose tissue67,75.     
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 Monocyte chemoattractant protein (MCP-1)  
MCP-1 is pro-inflammatory and promotes insulin resistance. The 
concentrations of MCP-1 have not been clearly established for subcutaneous 
compared to visceral adipose tissue, and in males compared to females, but studies 
suggest that concentrations may not vary by site or gender67,81,82.   
Plasminogen activator inhibitor (PAI-1) 
PAI-1, a protein of the hemostasis and fibrinolytic system, is secreted by 
adipocytes and functions to promote insulin resistance67. Higher concentrations of 
PAI-1 have been reported in visceral compared to subcutaneous adipose tissue.   
 Proteins of the renin angiotensin system (RAS) 
Adipose tissue secretes many of the RAS proteins which are involved in 
blood pressure regulation67.   
Visfatin 
Visfatin, which was discovered in 2005, promotes hyperglycemia83,84. Higher 
concentrations were found in visceral compared to subcutaneous adipose tissue83. 
This description above of the various functions of the adipose organ emphasizes the 
importance of adiposity measurements.  
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Table 3. Summary of adipokines and their functions associated with adiposity and 
cardio-metabolic risk factors 








risk factor(s) of 
interest 
Leptin 







2.  enhances insulin 




3.  increases blood 
pressure       
IL-6 1.  pro-inflammatory higher in visceral not established glucose 
  
2.  impairs glucose 
tolerance       
  
3.  promotes insulin 
resistance       






2.  enhances insulin 
sensitivity     LDL-C 
  
3.  reduces glucose 
synthesis       
  
4.  reduces oxidation of 
LDL-C       
ASP 
1. promotes insulin 
resistance not established not established glucose 
  
2.  promotes 
dyslipidemia     LDL-C 
TNFα 1.  pro-inflammatory 
higher in 
subcutaneous not established glucose 
  
2.  impairs insulin 
signaling       
MCP-1 
1.  promotes insulin 
resistance not established not established glucose 
  2.  pro-inflammatory       
PAI-1 
promotes insulin 
resistance higher in visceral not established glucose 
RAS 
proteins 
1.  blood pressure 




1.  promotes 
hyperglycemia higher in visceral not established glucose 
*IL-6: interleukin 6; LDL-C: low-density lipoprotein cholesterol; ASP: acylation stimulating protein; 
TNFα: tumor necrosis factor alpha; MCP-1: monocyte chemoattractant protein-1; PAI-1: 
plasminogen activator inhibitor 1; RAS: renin angiotensin system. 
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2.4 Measurements of adiposity 
BMI is measured as weight (kg) divided by the square of height (m2), 
therefore BMI is an imperfect measure of body fatness as BMI does not measure fat 
mass directly85. Yet, BMI is the most frequently used measure of an individual's 
weight status and is highly correlated with waist circumference (WC) and adiposity 
imaging methods86. The Institute of Medicine (IOM) report on measuring obesity 
concluded that BMI is a non-invasive inexpensive surrogate marker of the degree of 
fat distribution that is easy to calculate and effective for showing trends in 
populations and subgroups87. Advantages of using BMI to measure adiposity include 
its accuracy compared to weight alone, reliability as an indicator of total body fatness 
in both women and men, its ability as a marker of obesity-related cardio-metabolic 
risk, and its associations with morbidity and mortality86. BMI also has less observer 
variability compared to other non-invasive anthropometric techniques, since 
standardized and calibrated scales can be used86,88. For example, the use of WC in 
population settings to assess health risks depends on presence or absence of other 
risk factors (overweight, CVD, and type 2 diabetes) and could introduce 
measurement bias, because there is a lack of universal agreement on defining a 
single bone landmark to do the measurement88. 
Other adiposity measurement methods at the organ level that have high 
accuracy are imaging techniques such as computed axial tomography (CT) 
magnetic resonance imaging (MRI) and multi-detector computed tomography 
(MDCT), although these methods are associated with high costs86. One of the most 
accurate and precise measures of total body fat is dual energy x-ray absorptiometry 
(DXA), but DXA requires specialized systems and x-ray exposure86. The benefit of 
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using these higher accuracy methods over BMI in population studies does not 
overcome the associated cost and risks. A feasibility study comparing MDCT to 
other methods to evaluate visceral abdominal fat reported that MDCT measures 
were highly correlated with total visceral abdominal fat and with BMI86.  
Waist-to-hip ratio (WHR), a marker of visceral fat, is a simple and widely used 
method to characterize body fat distribution89. Specific protocols of hip 
measurements taken at the widest level over the trochanters and waist 
measurement around the abdomen, just above the hip bone must be followed to 
avoid measurement error89. Although WHR was found to be associated with disease 
risk and mortality in both males and females, WHR is partially independent of total 
adiposity86. Since total adiposity is related to many morbid conditions including CVD, 
WHR may not detect total adiposity in cases where both hip and WC vary while 
keeping the same ratio90.   
WC has a closer association with CVD risk factors and with other health 
indicators than does WHR91. WC estimates body girth at the abdomen and is a good 
surrogate index of visceral adiposity86. Visceral fat measures obtained by imaging 
are highly correlated with WC. Overall, WC is a helpful index of visceral adiposity 
among different racial groups, but can be subject to measurement error and operator 
variability86.      
The rationale for use of BMI as a proxy for change in adiposity in this 
dissertation was further highlighted in a study by Flegal et al. that compared 
percentage body fat to BMI, WC, and Waist-Stature ratio (WSR) in the 1994-2004 
NHANES populations85. A high degree of correlation was seen between BMI, WC 
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and WSR. These authors concluded that although BMI, WC and WSR may be 
inaccurate measure of body fatness, these measures are highly correlated with each 
other and correspond fairly well with percentage body fat within sex-age groups. BMI 
can be easily and accurately measured and is highly correlated with other more 
costly measures of adiposity. Particularly as a measure of change in adiposity, BMI 
has the advantage of a lower measurement error than those of WC and WSR, with 
the resulting reduction in opportunities for bias in the estimation of change. For the 
above reasons BMI and WC were chosen for characterization of change in general 
(BMI) and central (WC) adiposity for this doctoral research. The ARIC study 
examination protocol provides for standardized measurements of weight, height, and 
WC across study sites and repeat examinations, with documentation of 
measurement repeatability and of variability by technician92. 
2.5 Population prevention strategies  
Although persuasive work on the impact of shifts of small magnitude in the 
population distribution of blood pressure on the risk for CHD and stroke has been 
conducted93-95, little work of this kind has been reported to date to assess the 
population impact of modest changes in adiposity, despite the dynamic nature of 
adiposity distributions in the young96.  
Although only a few population-based prospective studies have examined the 
relationship between changes in BMI (measured as a continuous variable) and 
changes in cardio-metabolic risk factors (measured as continuous variables)11,  
Droyvold et al.97 examined the association between BMI and blood pressure using 
data from the Nord-Trondelag Health Study (HUNT). Among this group of 29,817 
participants of mean age 50 years, changes in BMI had an independent effect on 
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changes in SBP in both sexes. Findings from the multicenter longitudinal bi-racial 
Coronary Artery Risk Development in Young Adults (CARDIA) study of 3,095 
participants showed that the strongest predictor of both insulin resistance and 
increase in glucose levels was an increase in BMI11. Increases in adiposity, whether 
measured as BMI or % body fat were associated with adverse changes in blood 
pressure, lipids, and insulin levels regardless of initial weight, age, race or gender98.  
A linear association has also been shown between weight gain and increased levels 
of C-reactive protein, a measure of systemic inflammation, thereby providing a 
mechanism to explain some of the association between adiposity and cardio-
metabolic risk factors13. 
Considering the marked temporal trends of increasing adiposity99, the 
evidence that the cardio-metabolic risk factors associated with the detrimental health 
effects of adiposity can be reversed with weight loss15,100, and the growing burden of 
CVD33, primary prevention strategies at a population level are an urgent and 
important need. Associations between adiposity and cardio-metabolic risk factors 
extend beyond categorically defined obesity to adiposity in the modal region of the 
population distribution28,101. For this dissertation, we used methods already 
described for blood pressure and CVD outcomes. A large proportion of blood 
pressure - related CVD events occur in individuals within the modal region of the 
population distribution where blood pressure falls below the threshold for 
antihypertensive drug therapy. Three studies in particular highlighted the impact of 
small shifts in the population distribution of blood pressure on the risk of CHD 
events93-95. One study using data from the Third National Health and Examination 
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Survey (NHANES III) examined the impact on occurrence of CHD events associated 
with small shifts in the population distribution of SBP that would be seen through 
population-wide adoption of the Dietary Approaches to Stop Hypertension (DASH) 
diet95. After adjusting for race and baseline SBP, a population-wide SBP reduction of 
5.5 mmHg was associated with a reduction of 416,514 CHD events. A greater 
relative reduction was observed for African Americans95. 
Another study used data from the Framingham study and NHANES II to 
estimate the impact of small reductions in the population-wide distribution of diastolic 
blood pressure (DBP) through population-wide lifestyle modification on CHD and 
stroke. These authors found that a population-wide reduction of 2 mmHg in DBP 
would result in a 6% reduction in risk of CHD and a 15% reduction in risk of stroke 
and transient ischemic attacks (TIA)93.  An overall upward shift in the population 
distribution of BMI over time has been described across the NHANES and 
Framingham data, suggesting the need to address the predictors of adverse health 
effects associated with adiposity at the population level and the health benefits of 
arresting current trends rather than focusing only on the individual99. Similar to blood 
pressure, a large proportion of adiposity – related CVD events would likely occur in 
the modal region of the population distribution. The individuals in this region would 
not be classified as obese and would therefore fall below the threshold category for 
being classified as high-risk. For this dissertation, we hypothesized that small 
population-wide reductions in BMI and WC would be associated with significant 
reductions in CVD burden.  
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Further support for lifestyle modifications using population level strategies for 
reduction of cardio-metabolic risk factors was reported in a meta-analysis of 23 
RCTs conducted between 1996 and 2011 in multiple countries102. These authors 
examined the effects of low-carbohydrate diets versus low-fat diets on metabolic risk 
factors. Reductions in body weight, WC, and other metabolic risk factors were not 
significantly different between the two diets. Both diet intervention types showed that 
lifestyle modifications achieved small reductions in weight that were associated with 
reductions in cardio-metabolic risk factors including total cholesterol, LDL, HDL, 
triglycerides, SBP and DBP, FPG and insulin.   
Recommendations for achieving the goal of the American Heart Association 
(AHA) to improve cardiovascular health 20% by 2020 include nationwide primordial 
prevention efforts at the population and individual level9. The paradigm of prevention 
strategies proposed by Rose103,104 emphasized the importance of population 
prevention strategies for risk factors and their associated chronic diseases since 
“high risk” prevention strategies that focus on the individual are limited in their ability 
to reduce burden of disease in the population. The individual-centered or “high-risk” 
strategy aims to truncate the risk distribution, whereas the population strategy aims 
to reduce disease outcomes by shifting the whole population distribution of a risk 
factor in a favorable direction. Because a large number of outcomes occur in the 
modal region of the distribution, a shift in the whole distribution of the risk factor 
would likely reduce outcomes more effectively than a truncation of the upper tail 
region of the distribution.   
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For this dissertation, we examined methods of prevention that move away 
from the individual-centered approach and towards a population-based approach. 
This would offer better measures of etiological outcome and public health 
importance104.    
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CHAPTER 3: PRELIMINARY STUDIES 
Across the 4 race-gender groups in the Atherosclerosis Risk in Communities 
(ARIC) study, baseline mean values of BMI and SBP were the highest in African 
American women. Baseline mean values of LDL-C and glucose were the highest in 
white men and African American men respectively. White women had the lowest 
values for BMI, SBP, LDL-C and glucose among the 4 race gender groups (Table 
4)1. Mean change in BMI between ARIC visits one and two varied between 0.2 to 0.5 
kg/m2 with the largest changes in white women and the smallest changes in white 
men (Table 5). Weight loss of 3% or greater of body weight over a 3-year follow-up 
was recorded for 1,026 ARIC participants who were overweight at baseline. The 
number previously overweight who showed weight loss of this magnitude over the 
course of 9-years is 3472.
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Table 4. Baseline mean (standard deviation SD) and number of observations (N) 
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2. Truesdale KP, Stevens J, Cai J. The effect of weight history on glucose and 
lipids: the Atherosclerosis Risk in Communities Study. American Journal of 
Epidemiology. 2005;161(12):1133-1143. 
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CHAPTER 4: INNOVATION 
To our knowledge, this was the first study to estimate the association 
between small shifts in the population distribution of adiposity and both cardio-
metabolic risk factors and their associated CVD burden. This work builds upon 
observational and intervention studies that focused on overweight individuals or 
those defined as obese, mostly without documentation of their cultural affiliation or 
minority status. To address these gaps in our knowledge, we calibrated the best 
evidence on the effect of changes in adiposity on metabolic risk factors available 
from the literature, to populations of African American and white men and women. 
These population-based effects were the basis for the estimation of the impact on 
CVD burden that public health scientists and policy makers can consider in the 
formulation of approaches to population-based prevention of chronic diseases. The 
quantification of the impact attributed to small changes of adiposity at a population 
level, of a magnitude shown to be achievable through lifestyle intervention may 
contribute novel information to the information base needed in the public health 
sciences and health policy administration. 
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CHAPTER 5: POTENTIAL IMPACT 
Several reasons emphasize the potential high impact of this doctoral 
research. Deaths and disability from CVD continue to be a major public health 
problem, driven in part by population-wide increases in adiposity with origins early in 
life. The association between upstream adiposity and metabolic risk factors, and the 
link between cardio-metabolic risk factors and the burden of CVD have been 
established in observational studies and randomized clinical trials. This modern 
epidemic is a source of significant health disparities, derived from a high prevalence 
of adiposity, and a greater burden of CVD manifestations in most U.S. minority 
groups. The magnitude of this public health problem exceeds by far societal 
resources for individual-level amelioration, to which are added the known difficulties 
of individual behavioral changes. Primary prevention strategies at a population level 
to reduce risk factors for CVD are therefore crucial. Our study explored a novel 
approach to the study of  prevention-oriented small changes in adiposity assosciated 
with cardio-metabolic risk factors and the CVD burden in the popuation.
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CHAPTER 6: METHODS 
6.1 Study population 
This study utilized data from the Atherosclerosis Risk in Communities (ARIC) 
study, a community-based prospective cohort, designed to investigate the etiology of 
atherosclerosis and its clinical manifestations. The ARIC study also measures 
variation in cardiovascular disease (CVD)-related risk factors, medical care, 
prevalence and incidence by race, gender, place and time. Study participants were 
recruited as a probability sample of 15,792 African American and white adults aged 
45-64 years, from four US communities including Forsyth County, North Carolina; 
Jackson, Mississippi; suburbs of Minneapolis, Minnesota; and Washington County, 
Maryland. African American participants represent 100% of those sampled in the 
Jackson community. In Forsyth County, 12% of the eligible sample was African 
American. Washington County, MD and Minneapolis, MN sampled primarily white 
participants.   
Demographic and health characteristics were collected during home 
interviews, with response rates of approximately 75% in each community. Among 
individuals who completed the home interview, rates of attendance at the first clinic 
examination varied from 63% (Jackson) to 88% in the other three communities. The 
follow-up rates among individuals who were alive at each visit were 93, 86 and 81% 
at visits two, three, and four respectively. The Institutional Review Boards at each 
site approved the ARIC study and all participants completed the informed consent1,2. 
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6.2 ARIC study visits and follow-up 
ARIC participants have completed five study visits. Our study included the 
first four visits, which began in 1987 and were conducted approximately three years 
apart. At each visit, standardized physical examinations and interviewer-
administered questionnaires were conducted to gather behavioral information, 
medical data, contextual data, and other relevant atherosclerosis risk 
measurements. All measurements taken at the ARIC examinations were collected 
by trained technicians following a common study protocol standardized across the 
repeat examination visits1. Participants were asked not to eat or drink anything other 
than water 12-hours prior to and to refrain from smoking 1-hour prior to ARIC study 
visits.   
Annual follow-up interviews and semi-annual review of hospitalization records 
and death certificates were conducted (and are ongoing) to ascertain outcome 
information. We included a median total of 12 years of follow-up information, thereby 
analyzing outcome data through 2002. The overall goal of our study was to estimate 
the total effect of a hypothetical reduction in adiposity on disease risk.   
6.3 Exposure, covariate and outcome ascertainment 
 Covariate information was ascertained during each of the 4 triennial study 
visits for BMI (kg/m2), WC (cm), cigarette smoking status (current compared to never 
and previous), hypertension (blood pressure>140/90 mmHg or use of anti-
hypertension medication within 2 weeks), and diabetes (fasting plasma glucose 
(FPG) >126 mg/dL or non-fasting glucose > 200 mg/dL or self-report of physician 
diagnosis or treatment with hypoglycemic agents).  
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6.4 Outcome assessment 
 The study outcomes [peripheral artery disease (PAD) and coronary heart 
disease (CHD)] correspond to those ascertained and classified by the ARIC 
investigators and released as CHD events, consistent with those published by ARIC. 
Participants were followed until the first occurrence of incident outcome, outcome-
related death, non-outcome related death or absence from an ARIC examination 
visit. If participants missed a study visit they were considered at risk for incidence of 
the study outcome, study outcome death and non-study outcome death for three 
years after that missed visit. For the purposes of this study, we administratively 
censored individuals 3 years after the 4th visit 
6.4.1 PAD 
Incident PAD events were identified using ICD-9-CM codes for PAD and CLI24 
(443.1, 443.22, 443.81, 443.89, 443.9, 440.20, 440.21, 440.29, 440.30, 440.31, 
440.32, 440.4, 440.8, 440.22, 440.23, 39.25, 39.29, 38.18, 38.38, and 38.48) from 
active surveillance of hospitalizations.  
6.4.2 CHD 
Ascertainment of CHD events was conducted through annual telephone 
interviews of health events and hospitalizations, an active surveillance of discharge 
lists from local hospitals and death certificates from state vital statistics offices. CHD 
events were validated by a morbidity and mortality classification committee. We 
defined incident CHD as the first occurrence of definite or probable hospitalized 




For the aim 1 analysis, we excluded participants with self-reported cancer at 
baseline, participants reporting use of heart failure medication within the two weeks 
prior to visit 1, and participants with an estimated Glomerular Filtration Rate (eGFR) 
< 15 mL/min/1.73 m2 using the Chronic Kidney Disease Epidemiology Collaboration 
(CKD-EPI) equation. We also trimmed 1% of the lower and upper tails of the BMI 
distribution.  
For aims 2-4, of the 15,792 ARIC participants who attended the ARIC 
baseline visit we excluded individuals who reported a race other than African 
American or white (n=48) and 55 African Americans from Minnesota or Washington 
county because of small site-specific numbers. Also excluded were participants who 
at baseline reported morbidity/chronic conditions associated with weight gain or loss, 
including 871 with self-reported cancer; 79 taking heart failure medication; 19 with 
kidney failure (eGFR<15 mL/min/1.73m2); and 144 missing data on kidney function.  
For the PAD analysis we excluded 632 individuals with prevalent PAD. 
Participants with missing data on baseline covariates and covariates related to 
exclusion criteria were excluded; 58 missing BMI, smoking, hypertension, or 
diabetes. After applying these exclusions, we removed outliers by trimming 
observations above the race-gender-specific  99th percentile of BMI (50.4 kg/m2, 
43.7 kg/m2, 42.0 kg/m2, and 39.8 kg/m2 for African American women, white women, 
African American men and white men, respectively) or lower than the 1st percentile 
(18.8 kg/m2, 18.1 kg/m2, 18.0 kg/m2, and 19.9 kg/m2  for African American women, 
white women, African American men and white men respectively) of the baseline 
BMI distribution (n=282), to arrive at our analytic set of 13,604 individuals.  
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We excluded 667 individuals with prevalent CHD for the CHD analysis. We 
excluded participants with missing data on baseline covariates and covariates 
related to exclusion criteria. For the analysis of the effect of a hypothetical shift in 
BMI, we excluded 58 individuals missing BMI, smoking, hypertension, or diabetes 
and removed outliers by trimming observations above the race-gender-specific 99th 
percentile of BMI (kg/m2)  (50.3, 43.5, 42.0, and 39.6 for African American women, 
white women, African American men and white men, respectively) or lower than the 
1st percentile (18.8, 18.1, 18.0, and 19.9 kg/m2  for African American women, white 
women, African American men and white men respectively) of the baseline BMI 
distribution (n=241), to arrive at our analytic set of 13,610 individuals. To arrive at 
our analytic set of 13,301 individuals for the WC analysis, we excluded 305 
individuals missing WC, smoking or BMI, and trimmed observations below the race-
gender-specific 1st percentile and above the 99th percentile of the baseline 
distribution of WC (cm). The 99th percentile of WC was 140, 130, 127, and 124 for 
African American women, white women, African American men and white men, 
respectively and the 1st percentile of WC was 70, 68, 99, and 99 cm for African 
American women, white women, African American men and white men respectively. 
6.6 Overview 
We calculated baseline frequency and percent of selected categorical 
variables (race, gender, smoking status, prevalence of hypertension, diabetes, PAD 
and CHD, and prevalence of morbidity/chronic conditions associated with 
unintentional weight gain or loss) and mean and SD of BMI and age. The total effect 
of BMI on the specified chronic diseases occurs through multiple biological 
pathways. SBP and FPG are two salient cardio-metabolic risk factors along the 
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pathways through which BMI affects advanced PAD and CHD.  Therefore, we 
described the cross-sectional associations between BMI and SBP and glucose in the 
ARIC population compared to that in the human experimental literature (Aim 1). We 
applied 5% hypothetical shifts to the population distribution of BMI and WC and 
estimated changes in the risk, for the specified CVDs - PAD (Aim 2) and CHD (Aims 
3 and 4).   
6.7 Statistical analysis 
6.7.1 Association between BMI and SBP and BMI and glucose. [Aim 1] 
All analyses were conducted using linear regression (proc reg procedure in 
SAS) at baseline across strata of race and gender. We examined separate analyses 
for SBP and FPG. SBP and FPG were included as continuous outcome variables 
and BMI was the main exposure variable in the model. We centered BMI to the 2000 
National Health and Nutrition Examination Survey (NHANES) mean for the US 
population. Age was included in the model centered to 55 years old. Smoking was 
included as a binary variable for current versus never and former smokers. The 
following models are for SBP and the same methods were followed for FPG as the 
outcome variable.   
Model 1:  SBP =B0 (intercept) + B1 (BMI) + B2 (age) + B3 (smoking status) 
Model 2: SBP= (Model 1) + B4 (BMI2) 
6.7.2 Cross-sectional association in the ARIC cohort [Aim 1] 
The cross-sectional association between BMI and SBP and FPG was 
estimated at each of the four ARIC study visits using the following linear regression 
model:  
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Equation 1: Y=β0+β1(BMI)+β2(age)+β3(smoking)+(ԑ);  
where Y was SBP in one model and FPG in a separate model, β0 was the 
intercept, β1 represented the difference in Y given a 1-unit increase in BMI 
controlled for the confounders - β2(age as a continuous variable) and 
β3(dichotomous variable for current smoking). 
This association was stratified by birth cohort (45-54 or 55-64 years of age at 
baseline), race and gender. We conducted linear regression analysis to determine 
the association with BMI included in the model along with its polynomials to test for 
linearity.  
6.7.3 Comparison of the cross-sectional association in ARIC to the effect 
estimates in the human experimental literature [Aim 1] 
Estimates of the association between BMI and SBP and glucose have been 
reported in the human experimental literature. In the human experimental literature,3-
5 for every 1-unit decrease in BMI, reductions in SBP ranged from 0.33 to 4.33 
mmHg and reductions in FPG ranged from 0.81 to 9.11 mg/dL. The magnitude of the 
differences in SBP and glucose predicted using linear regression analysis in ARIC 
for a 1-unit change in BMI were compared to the estimates found in the human 
experimental literature 3-5,6.   
Parametric g-formula [Aims 2-4] 











We used the parametric g-formula to estimate the change in incidence of 
PAD and CHD following hypothetical changes in the population distribution of 
adiposity. Briefly, the parametric g-formula25 draws on probability modeling, 
standardization and Monte Carlo sampling for an estimation of the effects of 
hypothetical interventions from longitudinal data40-43. The parametric g-formula is 
based on several assumptions one of which is that all joint predictors of the outcome 
and exposure are measured at all time points for which risk predictions of the 
outcome are made. Since outcome information was available as date of incident 
PAD and CHD we classified PAD and CHD as annual incidence, thereby creating a 
person-year analytic set from which we estimated cumulative incidence of PAD and 
CHD. WC, BMI, diabetes, hypertension and smoking status were assessed at ARIC 
examination visits, which occurred at approximately 3-year intervals. We used a 
carry forward method to fill in the covariates between ARIC study visits and to create 
a person-year dataset.  
6.7.4 Probability modeling 
We describe the following sections (Probability modeling, Monte Carlo 
sampling, and Effect estimation) using CHD as an example and the same procedure 
was followed for the analysis of BMI and PAD. We constructed regression models to 
predict the probability of CHD, death, censoring and all of the time-varying 
covariates for each person-year from baseline through the end of follow-up. Baseline 
covariates included in each of the regression models were race, sex, and education. 
Age was included in all models as a time-varying covariate. Pooled logistic 
regression was used to predict the probability of CHD for each person-year. Binary 
time-varying covariates were modeled using pooled logistic regression, and BMI and 
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WC were included as continuous variables and modeled using pooled linear 
regression.     
6.7.5 Monte Carlo sampling 
The probability of developing CHD between baseline and end of follow-up 
was estimated using a Monte Carlo approximation based on the intervention-specific 
joint distribution of CHD, death, censoring, BMI, WC and all time-varying and time-
fixed confounders. Our original datasets of 13,610 for the BMI analysis and 13,301 
for the WC analysis were re-sampled with replacement for M=1,360,000 and 
M=1,330,000 “pseudo-participants” respectively yielding the empirical distribution of 
all baseline covariates. We then simulated time-varying covariate and outcome data 
for each of the “pseudo participants” using the conditional probabilities estimated in 
the probability models above, and generated a simulated population for which the 
joint distribution of CHD and the risk factors was approximately equal to the joint 
distribution implied by the parametric g-formula. No hypothetical adiposity reduction 
was applied to this simulated dataset, which is identified as the “natural course”. 
6.7.6  Effect estimation 
Using the parametric g-formula we estimated the cumulative incidence of 
CHD under four scenarios; natural course where no BMI change was applied for the 
BMI analysis, natural course where no WC change was applied for the WC analysis, 
a 5% annual reduction in BMI relative to the trajectory of BMI from the natural course 
within the population who had a BMI > 24 kg/m2, and a 5% reduction in WC relative 
to the trajectory of WC from the natural course within the population who had a 
WC>88 cm. These shifts in BMI and WC relative to the natural course were applied 
only among those younger than 65 years of age and consistent with the usual 
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clinical recommendations for weight loss. The cumulative incidence of CHD was 
calculated using the SAS %CIF macro which estimates the cumulative incidence 
function while allowing for competing risks from death or censoring44. The risk 
difference and 95% CI were estimated under the two scenarios mentioned using 
non-parametric bootstrapping. The steps described above were repeated on 200 
random samples from the observed ARIC cohort with replacement, from which we 
estimated the standard error to calculate the 95% CI as cumulative incidence + 1.96 
X SD (cumulative incidence) and risk difference + 1.96 X SD (risk difference). All 
analyses were conducted using SAS 9.4 (Cary, NC).       
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CHAPTER 7: RESULTS OF AIM 1 
7.1 Results for SBP (Table 6)  
After adjusting for age and smoking status, the linear models (model 1) for 
African American women and white women had different parameter estimates for 
BMI as the 95% confidence intervals (CI) did not overlap (0.6, 95%CI: 0.4, 0.7 for 
African American women and 0.9, 95% CI: 0.8, 1.0 for white women). In comparison, 
the linear model for African American men and white men did have similar 
parameter estimates for centered BMI as these 95 % CI did overlap (0.5, 95% CI: 
0.3, 0. 8 for African American men and 0.8, 95% CI: 0.7, 1.0 for white women). The 
parameter estimates for BMI in the linear models were overlapping for African 
American women and men and for white women and men. The quadratic term 
(model 2) for BMI was not statistically significant for any of the race/sex strata.   
7.2 Results for glucose (Table 7)  
After adjusting for age and smoking status, all of the linear models (model 1) 
had similar parameter estimates for BMI with overlapping 95% CI across strata of 
race and sex. The quadratic term (model 2) for BMI was only statistically significant 
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CHAPTER 8: RESULTS MANUSCRIPT 1. CHANGES IN BURDEN OF 
PERIPHERAL ARTERY DISEASE FOLLOWING A HYPOTHETICAL CHANGE IN 
THE POPULATION DISTRIBUTION OF ADIPOSITY 
8.1 Introduction 
Shifting the population distribution of modifiable risk factors carries a large 
potential to reduce the burden of chronic diseases1, and sizeable reductions in 
myocardial infarction2 and stroke events are predicted from hypothetical lifestyle 
interventions targeting blood pressure, adiposity and other modifiable risk factors3,4. 
Consideration of adiposity for population-wide interventions to reduce the burden of 
chronic disease is salient as 30% of the world’s population is overweight or obese5, 
and adiposity is associated with several cardiovascular disease (CVD) risk factors 
and health outcomes. Furthermore, associations between adiposity, metabolic 
impairment and CVD extend beyond categorically-defined overweight and obesity to 
adiposity in the modal region of the population distribution6. The feasibility of 
population-wide interventions on adiposity has not been fully evaluated, yet 
interventions and policies have been proposed to reduce obesity at a population 
level through healthier eating and increased physical activity7-9. Although work has 
been done to estimate the reduction in disease burden following hypothetical shifts 
in the population distribution of various risk factors, such work has not been done for 
adiposity and peripheral artery disease (PAD), a costly and disabling atherosclerotic 
condition of the medium and large arteries 10. 
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The common clinical presentations of PAD range from intermittent 
claudication, or ischemic pain in the calf muscles on ambulation, to critical limb 
ischemia (CLI) characterized by markedly reduced blood flow to the lower 
extremities. The 5-year mortality associated with PAD is 15-30%, which is reported 
to increase to 1-year mortality of 25% once the condition progresses to CLI11. The 
prevalence of PAD is related to age (~3.0% at ages 45 to 64, to 13.4% among those 
65 years and older)12,13 and affects approximately 8.5 million adults in the U.S. The 
prevalence of PAD is thus expected to increase as the population ages14-16.  
PAD is the downstream outcome of behavioral, metabolic and environmental 
risk factors10. Null or inverse associations between BMI and PAD have been 
reported primarily by cross-sectional epidemiological studies that employed 
conventional analytic models to adjust for confounders17,18. In the setting of 
adiposity, elevated blood pressure, diabetes and dyslipoproteinemia are time-
varying risk factors that may lie on the causal pathway between body mass index 
(BMI) and PAD, and are affected in turn by previous BMI. Use of conventional 
regression methods restricted to adjustment for confounding typically does not 
appropriately adjust for time-varying covariates that are affected by previous 
exposure17. One method that does control for time-varying confounding by 
covariates that may act as both mediators and confounders, is the parametric g-
formula18, provided the availability of repeat measures of those covariates. The 
parametric g-formula has been used to examine the effects of hypothetical shifts in 
the population distribution of various risk factors on conditions such as coronary 
heart disease2, diabetes19, cancer20, HIV17, and asthma21, but similar work has not 
 59 
been done for adiposity and PAD to our knowledge. Therefore, the objective of our 
study was to apply the parametric g-formula to estimate the impact on PAD of 
hypothetical population shifts in BMI that are expected to primarily occur through 
changes in adiposity.  
8.2 Methods  
8.2.1 Study population 
This study was conducted in the Atherosclerosis Risk in Communities (ARIC) 
study cohort, which is described in detail elsewhere 22. Briefly, ARIC includes a 
community-based prospective cohort, designed to investigate the etiology of 
atherosclerosis and its clinical manifestations. The ARIC study also conducts 
epidemiological surveillance to measure variation in incidence of CVD health events 
by race, gender, place and time.  
ARIC cohort participants were first examined during 1987-1989, as a 
probability sample of 15,792 adults aged 45-64 years, from four US communities 
including Forsyth County, North Carolina; Jackson, Mississippi; suburbs of 
Minneapolis, Minnesota; and Washington County, Maryland. Only African American 
residents were sampled in the Jackson study area.  
Demographic and health characteristics were collected during home 
interviews with response rates of approximately 75% in each community. The 
completeness of follow-up among individuals who were alive at each visit were 93, 
86 and 81% at visits two (1990-1992), three (1993-1995), and four (1996-1998), 
respectively. Institutional Review Boards at each site approved the ARIC study and 
all participants completed an informed consent22,23. We limited our analysis to 
baseline and the three following triennial exams (1987-1998).  
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8.2.2 Exposure and covariate measurement 
At each ARIC visit, standardized physical examinations and interviewer-
administered questionnaires were used to gather behavioral information, medical 
data, contextual data, and other relevant atherosclerosis risk measurements. All 
measurements taken at the ARIC examinations were collected by trained 
technicians following a common study protocol standardized across the repeat 
examination visits22.During annual follow-up interviews health outcomes and 
hospitalizations were ascertained. 
8.2.3 Exposure, covariate and outcome ascertainment 
 Covariate information was ascertained during each of the 4 triennial study 
visits for BMI (kg/m2), cigarette smoking status (current compared to never and 
previous), hypertension (blood pressure>140/90 mmHg or use of anti-hypertension 
medication within 2 weeks), and diabetes (fasting plasma glucose (FPG) >126 
mg/dL or or non-fasting glucose > 200 mg/dL or self-report of physician diagnosis or 
treatment with hypoglycemic agents).  
Incident PAD events were identified using ICD-9-CM codes for PAD and CLI24 
(443.1, 443.22, 443.81, 443.89, 443.9, 440.20, 440.21, 440.29, 440.30, 440.31, 
440.32, 440.4, 440.8, 440.22, 440.23, 39.25, 39.29, 38.18, 38.38, and 38.48) from 
active surveillance of hospitalizations. Participants were followed until the first 
occurrence of incident PAD, death or absence from an ARIC examination visit. If 
participants missed a study visit, incidence of PAD and death were considered for 
three years after that missed visit. The analyses were truncated to a follow-up time 
of 3 years post the date of visit 4; all participants were administratively censored 
afterwards.  
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Annual follow-up interviews and review of hospitalization records and death 
certificates were conducted to ascertain and classify study outcomes. We analyzed 
outcome data up to three years following the last attended ARIC visit, through a 
median 12 years of follow-up per participant.  
8.2.4 Analysis   
Exclusions 
Of the 15,792 ARIC participants who attended the ARIC baseline visit, we 
excluded individuals who reported a race other than African American or white 
(n=48) and 55 African Americans from Minnesota or Washington county because of 
small site-specific numbers. Also excluded were participants who at baseline 
reported morbidity/chronic conditions associated with weight gain or loss, including 
871 with self-reported cancer; 79 taking heart failure medication; 19 with kidney 
failure (estimated Glomerular Filtration Rate [(eGFR)<15 mL/min/1.73m2]; 144 
missing data on kidney function, and 632 with prevalent PAD. Participants with 
missing data on baseline covariates and covariates related to exclusion criteria were 
excluded; 58 missing BMI, smoking, hypertension, or diabetes. After applying these 
exclusions, we removed outliers by trimming observations above the race-gender-
specific  99th percentile of BMI (50.4 kg/m2, 43.7 kg/m2, 42.0 kg/m2, and 39.8 kg/m2 
for African American women, white women, African American men and white men, 
respectively) or lower than the 1st percentile (18.8 kg/m2, 18.1 kg/m2, 18.0 kg/m2, 
and 19.9 kg/m2  for African American women, white women, African American men 
and white men respectively) of the baseline BMI distribution (n=282), to arrive at our 
analytic set of 13,604 individuals.  
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8.2.5 Statistical analysis 
Parametric g-formula 
We used the parametric g-formula to estimate the change in risk of PAD 
following a hypothetical change in the population distribution of BMI. The parametric 
g-formula2 approach includes probability modeling, standardization and Monte Carlo 
sampling which enable an estimation of the effects of hypothetical interventions from 
longitudinal data. Key assumptions of the parametric g-formula are that there is no 
residual confounding and no model misspecification. A third strong assumption is 
treatment version irrelevance, implying that the effect of a shift in BMI applied as a 
hypothetical change is the same as it would have been if it had occurred 
naturally18,20,25,26. 
The parametric g-formula further assumes that all joint predictors of the 
outcome and exposure are measured at all time points for which risk predictions of 
the outcome are being made. Since outcome information was available as date of 
incident event for PAD we classified PAD as yearly incidence, thereby creating a 
person-year analytic set from which we estimated yearly risk of PAD. BMI, diabetes, 
hypertension and smoking status were assessed at ARIC examination visits, which 
occurred at approximately 3-year intervals. We used a carry forward method to fill in 
the covariates between ARIC study visits and to create a person-year dataset.  
The parametric g-formula can be described as a 3-step algorithm: 1) 




Regression models were constructed to predict the probability of PAD, death, 
censoring and all of the time-varying covariates for each person-year starting at 
baseline through the end of follow-up. Baseline covariates included in each of the 
regression models were race, sex, and education. Age was included in all models as 
a time-varying covariate. Pooled logistic regression was used to predict the 
probability of PAD for each person-year. Binary time-varying covariates were 
modeled using pooled logistic regression and BMI was included as a continuous 
variable and modeled using pooled linear regression.     
Monte Carlo sampling 
Our implementation of the parametric g-formula utilized a Monte Carlo 
approximation of the probability of developing PAD between baseline and end of 
follow-up, based on the intervention-specific joint distribution of PAD, death, 
censoring, BMI, and all time-varying and time-fixed confounders. Our original 
dataset of 13,604 was re-sampled with replacement for M=1,360,400 “pseudo-
participants” yielding the empirical distribution of all baseline covariates. We then 
simulated time-varying covariate and outcome data for each of the “pseudo 
participants” using the conditional probabilities estimated in the probability models 
above, and generated a simulated population for which the joint distribution of PAD 
and the risk factors was approximately equal to the joint distribution implied by the 
parametric g-formula.  A hypothetical BMI reduction is not applied to this simulated 




Using the parametric g-formula we estimated the cumulative incidence under 
two scenarios; natural course where no BMI change was applied, and a 5% annual 
reduction in BMI relative to the trajectory of BMI from the natural course. These 
shifts in BMI relative to the natural course were applied only among those younger 
than 65 years of age who had a BMI > 24 kg/m2, to avoid applying a hypothetical 
population shift outside of the usual clinical recommendations for weight loss. The 
cumulative incidence of PAD was calculated using the SAS %CIF macro which 
estimates the cumulative incidence function while allowing for competing risks from 
death or censoring27. The risk difference and 95% CI were estimated under the two 
scenarios using non-parametric bootstrapping. The steps described above were 
repeated on 500 random samples from the observed ARIC cohort (N=13,604) with 
replacement, from which we estimated the standard error to calculate the 95% CI as 
cumulative incidence + 1.96 X SD (cumulative incidence) and risk difference + 1.96 
X SD (risk difference). All analyses were conducted using SAS 9.4 (Cary, NC).      
8.3 Results 
8.3.1 Characteristics of study participants  
At baseline, study participants had a median age of 54 years (IQR: 48, 59), 
were more likely to be female (54%), of white race (73%), and to have at least a high 
school education (77%). Cigarette smoking (27%) and diabetes (20%) were less 
common than hypertension (58%) among baseline participants. Study participants at 
baseline had a median BMI (kg/m2) of 26.9 (IQR: 24.1, 30.4) (Supplemental Table1).  
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During a median 11.8 (IQR: 9.0, 11.8) years of follow-up, 231 incident PAD 
events were identified. Participants with incident PAD were more likely to be male 
(69%), of white race (83%), and have less than a high school education (34%) 
compared to those without incident PAD. Smoking (51%), diabetes (45%) and 
hypertension (77%) were more frequent among those who developed incident PAD 
compared to those without incident PAD (Table 1). Participants who did not develop 
incident PAD had a more favorable cardio-metabolic risk profile compared to those 
who developed incident PAD. Specifically, among those who developed incident 
PAD: systolic blood pressure (SBP) was 127 mmHg (IQR: 113, 142); fasting plasma 
glucose (FPG) was 106 mg/dL (IQR: 98.2, 141.6); total cholesterol (TC) was 216 
mmHg (IQR: 194, 246); and high density lipoprotein (HDL) was 38.3 mmHg IQR: 
31.8, 49.1. Conversely, among those who did not develop incident PAD, SBP was 
118 mmHg (IQR: 108, 131), FPG was 99 mg/dL (IQR: 93, 107), TC was 212 mmHg 
(IQR: 186, 239) and HDL was 49.1 mmHg (IQR: 39.5, 61) (Table 1).  
The probability models used to create our natural course scenario included a 
cubic term for follow-up time and a restricted quadratic spline for BMI with knots at 
21.1 kg/m2, 25.8 kg/m2, and 29.4 kg/m2 (Figure 1). The cumulative incidence of PAD 
under the natural course was 1.89% (95%CI: 1.62, 2.17%) and 1.72% (95%CI: 1.46, 
2.08%) following the hypothetical BMI change (Figure 2). The risk difference was -
0.17% (95% CI: -0.38, 0.13%) comparing no BMI change to the hypothetical BMI 
change (Table 2).  
  
 66 
8.4 Conclusions and discussion  
We estimated the effects of a hypothetical change in the population 
distribution of BMI on the incidence of PAD. This shift of 5% in a population 
distribution of BMI, which is slightly above what may be considered weight 
maintenance (<3% change) is therefore considered feasible28 and may be achieved 
through population-wide interventions that reduce caloric intake such as taxes on 
sugary-beverages9 or subsidies on healthier foods7. Body weight reductions as low 
as 5% are associated with reduced incidence of cardio-metabolic risk factors29. We 
implemented a BMI shift that was consistent with the observed temporal variability in 
BMI, by reducing BMI annually by 5% relative to the natural course in individuals 
who were younger than 65 years of age and had a BMI >24 kg/m2. For example, if 
the natural course of an individual’s BMI (kg/m) at baseline, year 1, year 2 and year 
3 was 25.4, 24.3, 25.2, and 26.0 respectively, then after the 5% BMI intervention this 
individual’s BMI (kg/m2) at baseline, year 1, year 2 and year 3 was 24.1, 24, 24, and 
24.7 respectively.  The predicted result from this hypothetical intervention was a 
small reduction in the risk of PAD to follow this population-wide reduction in BMI.  
Several cross-sectional epidemiological studies have reported the absence 
of, or an inverse association between BMI and PAD14,30-35 using standard regression 
methods, although these studies may not have appropriately adjusted for time-
varying confounding that is affected by previous exposure. These studies were also 
limited in their ability to examine the longitudinal association between BMI and PAD 
following implementation of a BMI reduction at multiple time points. To overcome the 
limitations of standard analytic methods and to allow for application of our 
hypothetical BMI reduction at multiple time points, we used the parametric g-formula 
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as an approach that combines parametric regression modeling to obtain conditional 
probabilities and Monte Carlo sampling to approximate standardization and to 
estimate measures of effect18,20. 
As a result, we were able to consider feedback loops in the form of time-
varying confounders affected by prior exposure, and other dynamic systems for 
realistic modeling of the processes hypothesized to be associated with PAD as the 
study outcome36. Prior reports have applied the parametric g-formula to estimate the 
effects of different lifestyle interventions (and their combination) on complex chronic 
conditions such as coronary heart disease2, diabetes19, cancer20 and asthma21, and 
to estimate the effects of therapeutic interventions among individuals in treatment for 
HIV17. To our knowledge, such work has not been applied to PAD.  
A population-wide reduction in BMI of 5% over a median 11.8 years in a 
middle-aged, bi-racial cohort predicted a small (0.17%) reduction in the risk of PAD. 
The small magnitude of this estimated reduction in the risk of PAD attributed to a 
shift in the population distribution of BMI likely reflects the larger effects of PAD risk 
factors that are not influenced by BMI, such as cigarette smoking and age. Although 
impaired glucose metabolism and elevated blood pressure/hypertension may lie in 
part on the causal path between BMI and PAD, the effects of a 5% reduction in BMI 
are considered to be quite small in magnitude in this population-based cohort of men 
and women who were middle-aged at study enrollment.  
Conditional on several assumptions, observational study data can be used to 
mimic randomized experiments of pre-specified interventions, to compare the 
distribution of the outcome of interest among the hypothetical intervention groups37. 
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The main assumption on which our results rely is the absence of unmeasured 
confounding to be approximately true, in order to mimic a randomized experiment in 
an observational setting, in which populations are contrasted as a counterfactual. 
We focused on adiposity at the level of the population and its potential impact on an 
outcome (PAD) that demonstrably is influenced by a number of antecedent risk 
factors. Changes in adiposity, indexed in this instance by changes in BMI, have well 
established effects on the risk factors for PAD in the population, such as elevated 
blood pressure, insulin resistance, diabetes and impaired lipid metabolism. This 
provides a plausible basis for a reduction in BMI as a hypothetical intervention aimed 
at reducing the risk of an atherosclerotic sequela such as PAD. Cigarette smoking in 
contrast, the main risk factor for PAD other than age, is inversely associated with 
BMI and a reduction in BMI is not expected to lead to changes in the acute effects of 
smoking on the vasculature, nor to influence the effect of cumulative exposure to 
smoking on the risk of PAD.  The role of cigarette smoking as a cofounding factor 
has been incorporated in our model, and we did not observe qualitative differences 
in the association between BMI and the risk of PAD among those who smoked 
cigarettes or those who had diabetes.   
Adiposity is a complex trait, influenced by factors ranging from behaviors to 
social norms, education, ethnicity, economic factors and food marketing practices, 
and reductions in adiposity may be achieved through various means. While targeted 
interventions at the population level can be desirable and feasible, such as the 
reduction of salt content in processed foods, single interventions on complex traits 
such as adiposity are likely to be less relevant for population-based policy.  Further, 
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different methods to change adiposity in populations may influence the risk of PAD 
through mechanisms that do not involve BMI, even if they were to achieve the same 
value of BMI. Single interventions involving BMI reduction are thus sensitive to the 
treatment version irrelevance assumption, which states that the method by which 
BMI reduction occurs should not affect the outcome38, that is, whether the reduction 
occurs due to dietary, exercise, or other lifestyle changes should not affect our 
results. In our data, this effect is identified through natural reductions (or increases) 
in BMI, so our hypothetical intervention approximates what would occur if individuals 
were motivated to reduce BMI through their own means, or structural or contextual 
changes occurred that affected the energy balance throughout the population.  
The results presented in this paper predict that 9% of PAD cases occurring in 
this study population-based cohort over the course of 9 to12 years of follow-up could 
have been prevented by a 5% shift in the population distribution of BMI. This 
observation does not imply a causal inference, which would require a well-defined 
intervention, and preferably the manipulation of such an intervention. Instead, a shift 
in the population distribution of BMI may result from different types of intervention, 
some of which may affect the risk of PAD in ways that are not mediated through 
adiposity, and may differ across populations and over time.  
Consistent with previous reports21, our hypothetical shift of 5% from the 
natural trajectory of BMI can be considered of modest magnitude, and corresponds 
to changes that are actually observed in the population. We therefore submit that the 
intervention can be considered well-defined in the sense that it is observed in the 
data, even though a single mechanism is not specified through which reductions in 
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BMI occur in all individuals. We are sensitive to the unmeasured confounding that 
may occur if our analytic approach failed to adjust for PAD risk factors that influence 
one or more of the routes by which individuals reduce their BMI. By adjusting for 
population predictors of BMI that may also be independently associated with PAD, 
we have reduced the potential for such residual confounding. 
In this study we considered arguably realistic reductions in the population 
distribution of BMI, as sustained shifts in the dynamic factors that affect BMI in a 
population setting through unspecified combinations of behavioral, environmental, 
social and economic factors. To translate our findings to population interventions, 
modifiable behaviors and lifestyle factors would have to be identified and tested. 
Such efforts are not warranted at this point, given that our results predicted only 
small benefits on PAD from a modest reduction in the population distribution of BMI.   
Our study had limitations, such as the truncation of our follow-up time to a 
median length of follow-up of 11.8 years, as required to meet the assumption of the 
parametric-g formula to have exposure and outcome information at all time periods. 
Applying the parametric g-formula methodology to PAD ascertained over a longer 
period of follow-up would provide a more meaningful estimate of the effect of a 
population-wide impact in the distribution of BMI on PAD, but a long interval between 
examination visits 4 and 5 in ARIC prevented us from using information beyond 
2002.  A strength of our study is the use of the parametric g-formula to estimate the 
change in risk of PAD following a hypothetical intervention on an upstream PAD risk 
factor (BMI), considering that such work on BMI and PAD has not been reported in 
the literature.  
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Although we predict only a small effect on the risk of PAD following a modest 
population-wide shift in adiposity, our results may inform the need for further 
investigation in other populations or to older ages when PAD risk is highest. 
Investigation of this question in birth cohorts with a lower prevalence of smoking is 
similarly warranted to address the potential benefits of a population shift of adiposity 
on cardiovascular disease outcomes.  
Future analyses stratified by race may be warranted as the frequency of 
occurrence of PAD, like that of other cardiovascular diseases, is higher among 
African Americans15, whose cardiovascular risk profiles and burden of adverse 
health outcomes are higher than those of other population groups in the U.S. 39,40.  
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Table 8. Manuscript 1 Table 1. Characteristics of the study population at baseline by 
incidence of PAD status between 1987 and end of follow-up in 2011. The ARIC 
Study. 






Sex Female 71 (31) 7296 (55) 
Race African American 39 (17) 3587 (27) 
Education  < High school graduate 78 (34) 3057 (23) 
 High school graduate or vocational 
school  
81 (35) 5456 (41) 
 Some college or college graduate 72 (31) 4860 (36) 
Cigarette 
smoking  
Current 118 (51) 3614 (25) 
Diabetes FPG >126 mg/dL or self-report 
physician diagnosis 
 
102 (45) 2660 (20) 
Hypertension Blood pressure>140/90 mmHg or use 
of anti-hypertension medication within 
2 weeks 
178 (77) 7732 (58) 






 Follow-up time 6.8 (3.9, 8.9) 11.8 (9.0, 11.9) 
 Age (years) 59 (55,62) 54 (49, 59) 
 BMI (kg/m2) 27.5 (25.4, 31.5) 26.9 (24.1, 30.3) 
 SBP (mmHg) 127 (113,142)a 118 (108, 131)b 
FPG (mg/dL) 106 (98.2, 141.6) 99 (93, 107)     
 Total cholesterol (mg/dL) 216 (194, 246)a 212 (186, 239)* 
High density lipoprotein (HDL) 38.3 (31.8, 49.1)a 49.1 (39.5, 61)** 
aN=230  bN=13,353, *N=13,277, **N=13,279  
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Figure 1. Manuscript 1 Figure 1. Cumulative 12-year incidence of PAD comparing 




Figure 2. Manuscript 1 Figure 2. Cumulative 12-year incidence of PAD comparing 
the natural course to a hypothetical 5% shift in the population distribution of BMI 
 
Table 9. Manuscript 1 Table 2. Cumulative 12-year incidence and risk difference 
(95% confidence interval) for the natural course cohort compared to the cohort 
subjected to a hypothetical 5% shift in the population distribution of BMI 
Cohort Effect measureb  Estimate (%) 95% CIa 




Incidence 1.72 1.46, 2.08 




Risk difference -0.17 -0.38, 0.13 
aConfidence Interval (CI) 
bBaseline covariates include age, sex, race, and education. Time varying covariates include years at 
risk for PAD, diabetes, hypertension, smoking, and BMI. 
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Table 10. Manuscript 1 Supplemental Table 1. Baseline demographics and 
covariates of 13,604 ARIC participants 
Baseline 
characteristics 
 Number (%) 
Sex Female 7367 (54) 
Race African American 3626 (27) 
Education  < high school graduate 3131 (23) 
 High school graduate or 
vocational school  
 
5540 (41) 




Cigarette smoking  Current 3732 (27) 
Diabetes Fasting glucose >126 mg/dL or 
self-report physician diagnosis 
 
2777 (20) 
Hypertension Blood pressure>140/90 mmHg 
or use of anti-hypertension 





 Median Interquartile 
interval 
 Age (years) 54 48, 5 
 BMI (kg/m2) 26.9 24.1, 30.4 
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CHAPTER 9: MANUSCRIPT 2. CHANGES IN BURDEN OF CORONARY HEART 
DISEASE FOLLOWING HYPOTHETICAL REDUCTIONS IN GENERAL AND 
VISCERAL ADIPOSITY 
9.1 Introduction 
Coronary heart disease (CHD) is the leading cause of death in the world with 
7.4 million deaths in 20121. Although death attributable to CHD declined overall in 
the U.S. from 186.8 per 100,000 population in 2003 to 102.6 per 100,000 population 
in 2013, these declines were disparate across different race-gender subgroups and 
slower in certain groups such as African American women2,3.  
The incidence of CHD, which includes first myocardial infarction (MI) and fatal 
CHD also declined significantly from 1987 to 2011 and was differential by race-
gender groups4. These age-adjusted incidence rates per 1,000 population among 
were 3.7 in white men, 6.2 in African American men, 2.1 in white women, and 4.1 in 
African American women who were 35 to 84 year old participants in the 
Atherosclerosis Risk in Communities (ARIC) study3. While the mean predicted 10-
year risk for CHD among adults aged 30 to 74 years decreased from 7.2% during 
1999 to 2000 to 6.5% during 2009 to 2010, this risk increased non-significantly 
among African American women2.  
The public health burden of CHD is emphasized by the high health care costs 
of CHD, which are expected to double between 2013 and 20303, and the high 
mortality from CHD of which a large component includes sudden cardiac death 
(SCD)5,6. Continued progress in reducing mortality, incidence, and case-fatality 
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related to CHD requires sustained and expanded public health efforts aimed at 
prevention of CHD at the population level6.   
Modifiable risk factors for CHD are well established, such as hypertension7,8 
and diabetes9-11, while most of the CHD risk associated with overweight/obesity is 
mediated by the metabolic dysregulation associated with excess adiposity, with 
manifestations such as hypertension12-16 and diabetes3,17.  The causal role of excess 
adiposity on hypertension and diabetes is also well documented18.  Risk of CHD 
including SCD increases with increasing overweight and obesity9,19-21. The strength 
of the association between general (BMI) and central (WC) adiposity with CHD is of 
similar magnitude: a 1 standard deviation increment in BMI or WC is associated with 
a 25-30% higher risk of CVD including CHD22.  
Although excess adiposity is associated with CHD22,23 the effect of adiposity 
reduction on CHD risk is unclear24,25, and to our knowledge no randomized, 
controlled clinical trial has put this question to a test. Several observational studies 
have found increased adiposity to be predictive of increased risk of CHD26,27 while 
others have reported increased risk of CHD following weight loss28,29, and other 
studies reported no association24,30,31. Since the effect of adiposity on CHD risk likely 
occurs through the well documented, adverse effects of excess adiposity on cardio-
metabolic intermediates in the path to CHD, adiposity represents a modifiable, 
upstream risk factor for CHD 32.  
In 2015 an estimated 30.6% of U.S. adults were obese (BMI >30 kg/m2), 
which is slightly higher than the 29.9% prevalence estimate of adult obesity in 
201433. The prevalence of excess adiposity is even higher (69%) when including 
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those who are overweight (BMI=25-29.9 kg/m2) or obese. The national prevalence of 
elevated abdominal adiposity, defined using sex-specific cut points of WC, i.e. >88 
cm for women and >102 cm for men15, also has increased over time, differentially by 
sex and race34. The increases in the prevalence of excess abdominal adiposity from 
1999 to 2000 and 2010 to 2011 were greater than expected based on increases in 
BMI3.  
While previous reports examined the effect on CHD of hypothetical BMI 
interventions25,35, we considered both BMI and WC as measures of adiposity in our 
analysis, to estimate the effects on the incidence of CHD predicted from hypothetical 
interventions on general, as well as on central adiposity. As a surrogate measure for 
visceral fat, the more metabolically active adipose depot associated with production 
of adipokines and metabolic dysregulation36,37, WC has a potential but understudied 
role in the assessment and modification of CHD risk, since few studies have 
examined population-based reductions in general and/or central adiposity to reduce 
the public health burden for CHD24,25.  WC may also convey a simpler and more 
compelling public health message than BMI. The purpose of this study was to 
examine the effect of small hypothetical changes (5%) in two commonly used 
measures of general (BMI) and central adiposity (WC) on the incidence of CHD.              
9.2 Methods  
9.2.1 Study population 
This study was conducted in the community-based prospective 
Atherosclerosis Risk in Communities (ARIC) study cohort38, which was designed to 
investigate the etiology of atherosclerosis and its clinical manifestations. The ARIC 
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study also conducts epidemiological surveillance to measure variation in incidence 
of CVD health events by race, gender, place and time.  
ARIC cohort participants were first examined during 1987-1989, as a 
probability sample of 15,792 adults aged 45-64 years, from four US communities 
including Forsyth County, North Carolina; Jackson, Mississippi; suburbs of 
Minneapolis, Minnesota; and Washington County, Maryland. Only African American 
residents were sampled in the Jackson study area.  
Demographic and health characteristics were collected during home 
interviews with response rates of approximately 75% in each community. Follow-up 
interviews were carried out for 93, 86 and 81% of living individuals at visits two 
(1990-1992), three (1993-1995), and four (1996-1998), respectively. Institutional 
Review Boards at each site approved the ARIC study and all participants completed 
an informed consent38,39. We limited our analysis to baseline and the three following 
triennial exams (1987-1998).  
9.2.2 Exposure and covariate measurement 
At each ARIC visit, standardized physical examinations and interviewer-
administered questionnaires were used to gather behavioral information, medical 
data, contextual data, and other relevant atherosclerosis risk measurements. All 
measurements taken at the ARIC examinations were collected by trained 
technicians following a common study protocol standardized across the repeat 
examination visits38. Annual follow-up telephone interviews ascertained health 
outcomes and hospitalizations. 
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9.2.3 Exposure, covariate and outcome ascertainment 
 Covariate information was ascertained during each of the 4 triennial study 
visits for BMI (kg/m2), WC (cm), cigarette smoking status (current compared to never 
and previous), hypertension (blood pressure>140/90 mmHg or use of anti-
hypertension medication within 2 weeks), and diabetes (fasting plasma glucose 
(FPG) >126 mg/dL or non-fasting glucose > 200 mg/dL or self-report of physician 
diagnosis or treatment with hypoglycemic agents).  
Ascertainment of CHD events was conducted through annual telephone 
interviews of health events and hospitalizations, an active surveillance of discharge 
lists from local hospitals and death certificates from state vital statistics offices. CHD 
events were validated by a morbidity and mortality classification committee. We 
defined incident CHD as the first occurrence of definite or probable hospitalized 
myocardial infarction (MI), a definite CHD death, or an unrecognized MI. 
Participants were followed until the first occurrence of incident CHD, CHD 
death, non-CHD death or absence from an ARIC examination visit. If participants 
missed a study visit they were considered at risk for incidence of CHD, CHD death 
and non-CHD death for three years after that missed visit. For the purposes of this 
study, we administratively censored individuals 3 years after the 4th visit 
9.2.4 Analysis   
Exclusions 
Among the 15,792 ARIC participants who attended the ARIC baseline visit we 
excluded individuals who reported a race other than African American or white 
(n=48) and 55 African Americans from Minnesota or Washington county because of 
small site-specific numbers. Also excluded were participants who at baseline 
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reported morbidity/chronic conditions associated with weight gain or loss, including 
871 with self-reported cancer; 79 taking heart failure medication; 19 with kidney 
failure; 144 missing data on kidney function; and 667 with prevalent CHD. We 
excluded participants with missing data on baseline covariates and covariates 
related to exclusion criteria. For the analysis of the effect of a hypothetical shift in 
BMI, we excluded 58 individuals missing BMI, smoking, hypertension, or diabetes 
and removed outliers by trimming observations above the race-gender-specific 99th 
percentile of BMI (kg/m2)  (50.3, 43.5, 42.0, and 39.6 for African American women, 
white women, African American men and white men, respectively) or lower than the 
1st percentile (18.8, 18.1, 18.0, and 19.9 kg/m2  for African American women, white 
women, African American men and white men respectively) of the baseline BMI 
distribution (n=241), to arrive at our analytic set of 13,610 individuals. To arrive at 
our analytic set of 13,301 individuals for the WC analysis, we excluded 305 
individuals missing WC, smoking or BMI, and trimmed observations below the race-
gender-specific 1st percentile and above the 99th percentile of the baseline 
distribution of WC (cm). The 99th percentile of WC was 140, 130, 127, and 124 for 
African American women, white women, African American men and white men, 
respectively and the 1st percentile of WC was 70, 68, 99, and 99 cm for African 
American women, white women, African American men and white men respectively. 
9.2.5 Statistical analysis 
Parametric g-formula 
We used the parametric g-formula to estimate the change in incidence of 
CHD following hypothetical changes in the population distribution of adiposity. 
Briefly, the parametric g-formula25 draws on probability modeling, standardization 
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and Monte Carlo sampling for an estimation of the effects of hypothetical 
interventions from longitudinal data40-43. The parametric g-formula is based on 
several assumptions one of which is that all joint predictors of the outcome and 
exposure are measured at all time points for which risk predictions of the outcome 
are made. Since outcome information was available as date of incident CHD we 
classified CHD as annual incidence, thereby creating a person-year analytic set from 
which we estimated cumulative incidence of CHD. WC, BMI, diabetes, hypertension 
and smoking status were assessed at ARIC examination visits, which occurred at 
approximately 3-year intervals. We used a carry forward method to fill in the 
covariates between ARIC study visits and to create a person-year dataset.  
Probability modeling 
We constructed regression models to predict the probability of CHD, death, 
censoring and all of the time-varying covariates for each person-year from baseline 
through the end of follow-up. Baseline covariates included in each of the regression 
models were race, sex, and education. Age was included in all models as a time-
varying covariate. Pooled logistic regression was used to predict the probability of 
CHD for each person-year. Binary time-varying covariates were modeled using 
pooled logistic regression, and BMI and WC were included as continuous variables 
and modeled using pooled linear regression.     
Monte Carlo sampling 
The probability of developing CHD between baseline and end of follow-up 
was estimated using a Monte Carlo approximation based on the intervention-specific 
joint distribution of CHD, death, censoring, BMI, WC and all time-varying and time-
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fixed confounders. Our original datasets of 13,610 for the BMI analysis and 13,301 
for the WC analysis were re-sampled with replacement for M=1,360,000 and 
M=1,330,000 “pseudo-participants” respectively yielding the empirical distribution of 
all baseline covariates. We then simulated time-varying covariate and outcome data 
for each of the “pseudo participants” using the conditional probabilities estimated in 
the probability models above, and generated a simulated population for which the 
joint distribution of CHD and the risk factors was approximately equal to the joint 
distribution implied by the parametric g-formula.  No hypothetical adiposity reduction 
was applied to this simulated dataset, which is identified as the “natural course”. 
Effect estimation 
Using the parametric g-formula we estimated the cumulative incidence of 
CHD under four scenarios; natural course where no BMI change was applied for the 
BMI analysis, natural course where no WC change was applied for the WC analysis, 
a 5% annual reduction in BMI relative to the trajectory of BMI from the natural course 
within the population who had a BMI > 24 kg/m2, a 5% reduction in WC relative to 
the trajectory of WC from the natural course within the population who had a 
WC>88. These shifts in BMI and WC relative to the natural course were applied only 
among those younger than 65 years of age and consistent with the usual clinical 
recommendations for weight loss. The cumulative incidence of CHD was calculated 
using the SAS %CIF macro which estimates the cumulative incidence function while 
allowing for competing risks from death or censoring44. The risk difference and 95% 
CI were estimated under the two scenarios mentioned using non-parametric 
bootstrapping. The steps described above were repeated on 200 random samples 
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from the observed ARIC cohort (N=13,301) with replacement, from which we 
estimated the standard error to calculate the 95% CI as cumulative incidence + 1.96 
X SD (cumulative incidence) and risk difference + 1.96 X SD (risk difference). All 
analyses were conducted using SAS 9.4 (Cary, NC).      
9.3 Results 
9.3.1 Characteristics of study participants  
During a median 12 years of follow-up, 763 and 712 incident CHD events 
were identified among the 13,610 (BMI analysis) and 13,301 (WC analysis) middle-
aged men and women in this cohort. Participants who experienced incident CHD 
were older at baseline (median age=62 years), more likely to be male (67%), of 
white race (73%), and have less than a high school education (30%) compared to 
those without incident CHD. Smoking (29%), diabetes (28%) and hypertension 
(59%) were more frequent at baseline among those who developed incident CHD 
compared to those without incident CHD (Table 1). Participants who did not develop 
incident CHD had a more favorable cardio-metabolic risk profile compared to those 
who developed incident CHD. Specifically, baseline values among those who 
developed incident CHD were: 126 mmHg median systolic blood pressure (SBP); 
104 mg/dL median fasting plasma glucose (FPG); 221 mg/dL total cholesterol (TC) 
and 44 mg/dL high density lipoprotein (HDL) (Table 1).  
The probability models used to create the natural course scenario included a 
cubic term for follow-up time and a restricted quadratic spline for BMI with knots at 
21.1 kg/m2, 25.8 kg/m2, and 29.4 kg/m2 (Figure 1).  The difference in CHD incidence 
between the natural course and the hypothetical shift increased with follow-up time 
for both the BMI and WC analyses (Figure 2 and 3). The median BMI (kg/m2) was 
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between 26.9 and 28.18 in the natural course and between 24.7 and 25.6 in the 
population where a hypothetical 5% shift in BMI was applied (Figure 4). The median 
WC (cm) was between 95.9 and 100.6 in the natural course and between 88.6 and 
93.8 in the population exposed to a hypothetical 5% shift in WC (Figure 5). For the 
BMI analysis, the cumulative incidence of CHD under the natural course was 6.34% 
(95%CI: 5.90, 6.78%) and 5.78% (95%CI: 5.22, 6.35%) following the hypothetical 
BMI change. The risk difference was -0.56% (95% CI: -0.96, -0.14%) comparing no 
BMI change to the hypothetical BMI change (Table 2). For the waist circumference 
analysis, the cumulative incidence of CHD under the natural course was 6.21% 
(95%CI: 5.75, 6.67%) and 5.24% (95%CI: 4.60, 5.88%) following the hypothetical 
WC change. The risk difference was -0.96% (95% CI: -1.44, -0.48%) comparing no 
WC change to the hypothetical WC change (Table 2).  
9.4 Discussion/conclusions 
We estimated the effects of a hypothetical change in the population 
distribution of general (BMI) and central (WC) adiposity on the cumulative incidence 
of CHD in the ARIC study cohort. Moderate weight loss of 5-10% is recommended 
for people who are overweight45, although the mechanisms by which weight loss 
influences cardio-metabolic outcomes has been unclear. A recent randomized 
controlled trial (RCT) examined the effects of moderate weight loss (5-10%) on 
cardio-metabolic outcomes46 reporting that moderate weight loss improves metabolic 
function in several organs, including improvements in multi-organ insulin sensitivity, 
β cell function, and multiple risk factors for cardio-metabolic disease such as 
glucose, triglycerides, alanine transaminase, and leptin. A monotonic (‘dose-
response’) relationship between weight loss and key adipose tissue biological 
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pathways was observed. The results of this RCT lend plausibility to our results that 
9% and 16% of CHD events occurring in the ARIC study population over 12 years 
could have been prevented by a 5% shift in BMI and WC, respectively.  
The risk reduction in CHD was larger following a hypothetical 5% WC 
reduction compared to a hypothetical 5% BMI reduction, which may suggest a 
stronger metabolic impact of WC modifications and the associated risk of CHD. 
Other reasons for this difference to be considered are residual confounding if 
preclinical disease is present47, although we adjusted for baseline morbidity/chronic 
conditions related to weight change, and model misspecification. While correct 
model specification under the hypothetical reduction in adiposity cannot be 
demonstrated24, the models in the natural course were not substantially misspecified 
when comparing the natural course to the observed models to predict CHD.  
The effect of modest hypothetical shifts in the population distribution of BMI 
on incidence of CHD was previously examined24,25 using data from the Nurse’s 
Health Study25. The authors modeled several hypothetical lifestyle interventions, one 
of which targeted maintenance of a BMI<25 kg/m2. This hypothetical intervention 
was not predicted to have an effect on the incidence of CHD. The authors further 
stated that this particular hypothetical intervention on BMI was unrealistic since it 
would require that an individual at a BMI of 35 kg/m2 reduce her BMI to 25 kg/m2 in a 
2-year time period. Instead, the authors proposed, but did not test, a more realistic 
intervention to be one that reduces BMI by a small percentage (i.e. 5%)7.  
Although the effects on incidence of CHD following hypothetical modifications 
of BMI have been examined, other measures of adiposity have not been addressed, 
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to our knowledge. We therefore examined the effects on incidence of CHD following 
hypothetical modifications of two measures of adiposity – BMI and WC. BMI is the 
most frequently used measure of excess adiposity and is highly correlated with 
accurate yet expensive measures of adiposity such as multi-detector computed axial 
tomography (MDCT) and dual energy x-ray absorptiometry (DXA)48. Advantages of 
using BMI as a measure of adiposity include its ease of use and reliability as an 
indicator of total body fatness in women and men, its relationship with adiposity-
related cardio-metabolic risk, and its association with health outcomes49,50. While 
BMI is an index of general adiposity, WC is a surrogate index of visceral adiposity48 
and thus more closely associated with cardio-metabolic impairments on the pathway 
to CHD, including diabetes and hypertension51-56. The hypothetical WC reduction we 
applied at the 24th percentile of the WC distribution (WC> 88cm) predicted a larger 
risk reduction compared to a WC threshold at the gender-specific clinical guidelines 
that recommend a WC<88 cm for women and <102 cm for men3,57. In our study 
population, the percentile values that correspond to these gender-specific guidelines 
(<88 cm for women and <102 cm for men) are the 25th and 40th percentile for African 
American and white women respectively and the 73rd and 70th percentile for African 
American and white men respectively.  
The choice of adiposity measure in the formulation of population interventions 
and the development of public health messages aimed to reduce the risk of CHD 
deserve attention. Public health strategies to reduce excess adiposity typically 
consider the potential benefits and cost of interventions, which may favor a focus on 
central adiposity if the results presented here stand the test of replication. A focus on 
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central adiposity also opens opportunities for public health messages that address 
modification in WC or perhaps clothing size, as more tangible measures than a ratio 
formulation such as BMI. Although restricted in this case to CHD, the benefits we 
estimated would follow hypothetical shifts of small magnitude in the population 
distribution of adiposity suggesting that central adiposity should have a more 
prominent place in the public health efforts to modify the burden of excess adiposity 
in U.S. adults.   
Population-based programs to achieve sustained effects of modest 
magnitude but wide penetration are needed to complement clinical efforts that target 
excess adiposity, and to influence norms and trends that shift adiposity levels in 
populations23,58-61. Waist girth and central adiposity tap into cultural norms and 
popular perceptions different from those surrounding BMI and general 
adiposity3,62,63, as reflected in messages in the media and health product outlets. 
The work reported here estimated the potential benefit on the risk of incident CHD of 
hypothetical shifts in the population distribution of WC, comparing to that estimated 
for an equivalent hypothetical shift in the population distribution of general adiposity, 
indexed by BMI.  Our results suggest that central adiposity, approximated by a 
simple measure of WC is a population intervention target potentially superior to BMI. 
These results warrant replication in other population-based longitudinal studies with 
access to cultural, race/ethnic, and socioeconomic diversity. These results also call 
for assessments of the relative merit of hypothetical shifts in the distributions of WC 
and BMI on other health outcomes influenced by adiposity, more closely linked 
causally and in time lag to adiposity than is the case for CHD.  
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Several weaknesses of this study should be highlighted. To meet the 
assumptions built into the analytic model these analyses were limited to the initial 
three, consecutive re-examination visits of the ARIC cohort. As a result, the length of 
our follow-up is unlikely to fully capture the long term impact of adiposity at midlife on 
the risk of CHD during the life epochs when the incidence of CHD is highest. Since 
the use of WC as a measure of adiposity is reportedly not accurate in individuals 
with a BMI over 40 kg/m254 we excluded participants at the upper and lower 1% of 
the baseline population distribution of WC, which was also done for the analysis of 
BMI. Our estimates are therefore not generalizable to the segment of the population 
that exceeds this BMI threshold value. Strengths of our study derive from the 
estimation of the effect of a hypothetical reduction in BMI and of WC on the 
incidence of CHD in a bi-racial cohort of men and women, to our knowledge for the 
first time. We applied a hypothetical shift to the population distribution of adiposity at 
a threshold that was established to be near the clinical guidelines for excess 
adiposity15, which for our population was at the 24th percentile of the baseline 
distribution of BMI and WC. 
This report adds new information to the literature on the effects of 
hypothetical shifts in general and central adiposity on the incidence of CHD in a 
middle aged, bi-racial cohort. In the setting of a high population burden of overweight 
and obesity15, 33, 34 clinical as well public health efforts are needed to curb the 
epidemic of adiposity and control its societal impact on morbidity, survival, and cost 
of health care. Declines in mortality and incidence of CHD have been reported over 
the last decade and ongoing primary prevention of risk factors for CHD would be 
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required to continue the trajectory of these declines3,6. This report speaks to the 
important area of modest shifts in the population distribution of adiposity to influence 
an upstream condition that exerts a profound impact on health and longevity through 
metabolic dysregulation and its abnormalities. Estimation of the impact that can be 
achieved from small shifts in the population distribution of general and central 
adiposity indicated that a meaningful impact can be predicted on the risk of CHD, 
more so from a shift in central than in general adiposity. The population distribution 
of adiposity is dynamic, and subject to diverse influences23,57,64 and temporal 
trends65,66. Desirable shifts in population distributions of adiposity are the focus of 
public health policies aimed at serving sizes, limits on sugar-sweetened 
beverages,67-69 subsidies for healthier food choices, and increased accessibility for 
physical activity, among others. Using CHD as a sentinel condition, our results 
predict a modest effect on the incidence of CHD following small, population-wide 
shifts in central adiposity, and to a lesser degree in general adiposity. If replicated, 
these results can inform research into the effects of dynamic population distributions 
of various measures of adiposity toward public health efforts to reduce the 
population impact of adiposity.   
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Table 11. Manuscript 2 Table 1. Characteristics of the study population at baseline 
by incidence of CHD between 1987 and end of follow-up in 2011. The ARIC Study. 
(BMI analysis: N=13,610; WC analysis: N=13,301) 
 
Characteristic 
Incident CHD  
Number (%) 









WC analysis  
N=12,589  
Female 254 (33) 230 (32) 7356 (57) 7208 (57) 
African 
American 
207 (27) 190 (27) 3490 (47) 3419 (27) 
< HS graduate 230 (30) 211 (30) 2892 (23) 2828 (23) 
HS graduate or 
vocational 
school  






241 (32) 230 (32) 4681 (36) 4583 (36) 
Current 
smoking 
221 (29) 285 (40) 2032 (16) 3423 (27) 
Diabetes  213 (28) 242 (34) 1867 (15) 2402 (19) 
Hypertension  450 (59) 487 (68) 5995 (47) 7106 (57) 
 Median (Interquartile interval) Median (Interquartile interval) 
 BMI analysis WC analysis BMI analysis WC analysis 
Follow-up time 
(years) 
6.0 (3.0, 8.8) 5.8 (3.0, 8.6) 11.8 (9.0, 11.9) 11.8 (9.1, 11.9) 
Age (years) 62 (57,66) 62 (56, 66) 54 (49, 59) 63 (59, 68) 
BMI (kg/m2) 27.8 (25.1, 31.0) NA 26.8 (24.0, 30.3) NA 
WC (cm) NA 102 (94, 99) NA 100 (92, 99) 
SBP (mmHg) 126 (115, 140)a 126 (115, 140) 118 (108, 130)* 118 (108, 130) 
FPG (mg/dL) 104.0 (95, 122.3) 104.0 (95, 122.3) 99.0 (92.4, 106.9) 99 (92.4, 107) 
TC (mg/dL) 221 (195, 248)c 222 (196, 249) 212 (186, 239)*** 212 (186, 239) 
HDL 41.4 (34.7, 51.0)b 41 (34, 51) 50.0 (40.4, 61.6)** 49.1 (40.4, 61.6) 
High school: HS. Diabetes was defined as a fasting plasma glucose (FPG) >126 mg/dL or self-report 
physician diagnosis of diabetes. We defined hypertension as a blood pressure>140/90 mmHg or use 
of anti-hypertension medication within 2 weeks. Systolic blood pressure: SBP. Total cholesterol: TC. 
High density lipoprotein (HDL).  




Figure 3. Manuscript 2 Figure 1. Cumulative 12-year incidence of CHD comparing 




Figure 4. Manuscript 2 Figure 2. Cumulative 12-year incidence of CHD comparing 





Figure 5. Manuscript 2 Figure 3. Cumulative 12-year incidence of CHD comparing 




Figure 6. Manuscript 2 Figure 4. Median BMI (kg/m2) across increasing years of 
follow-up in the natural course and following the hypothetical 5% BMI reduction 
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Figure 7. Manuscript 2 Figure 5. Median waist circumference (WC) across 
increasing years of follow-up in the natural course and following the hypothetical 5% 



















Years of follow-up since baseline
Median BMI in the natural
course
Median BMI following the
hyothetical 5% BMI reduction
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Table 12. Manuscript 2 Table 2. Cumulative 12-year incidence and risk difference 
(95% confidence interval) of CHD for the natural course cohort compared to the 
cohort subjected to a hypothetical 5% shift in the population distribution of adiposity 
Cohort Estimanda  Estimate (%) 95% CIb 
Natural Course for 
BMI 




Incidence 5.78 5.22, 6.35 
Natural course vs. 
hypothetical 
reduction 
Risk difference -0.56 -0.96, -0.14 
Natural course for 
WC 
Incidence 6.21 5.75, 6.67 
Hypothetical 5% 
reduction in WC if 
WC>88 cm 
 
Incidence 5.24 4.60, 5.88 
Natural course vs. 
hypothetical WC 
reduction 
Risk difference -0.96 -1.44, -0.48 
    
aBaseline covariates include in the models were age, sex, race, and education 
Time-varying covariates included in the models were years at risk for CHD, diabetes, hypertension, 
smoking, and the measure of adiposity specific to each analysis of a hypothetical 5% reduction in 
general (BMI) or central (WC) adiposity.  
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CHAPTER 10: CONCLUSIONS 
10.1 Dissertation goal  
The overall goal of this doctoral research was to contribute to the 
understanding of the potential impact of moderate population-level changes in 
adiposity on specified cardiovascular diseases (CVD). Although the overall goal 
remained the same throughout this dissertation process, we sharpened the scope of 
the specific aims while meeting the overall dissertation goals within a reasonable 
time frame.  
10.2 Discussion of results  
We predicted a small but non-statistically significant reduction in the 
cumulative 12-year incidence of PAD [risk difference (RD):-0.17%, 95% confidence 
interval (CI): -0.38, 0.13] following a 5% population-wide reduction in BMI down to a 
BMI of 24 kg/m2 in adults younger than 65 years of age (MS#1). The small 
magnitude of this estimated reduction in the risk of PAD attributed to a shift in the 
population distribution of BMI likely reflects the larger effects of PAD risk factors that 
are not influenced by BMI, such as cigarette smoking and age. Although impaired 
glucose metabolism and elevated blood pressure/hypertension may lie in part on the 
causal path between BMI and PAD, the effects of a 5% reduction in BMI are 
considered to be quite small in magnitude in this population-based cohort of men 
and women who were middle-aged at study enrollment. 
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For MS#2, we estimated a -0.56% (95% CI: -0.96, -0.14%) reduction in the 
12-year cumulative incidence of CHD following a 5% shift in BMI down to a BMI of 
24 kg/m2 in adults younger than 65 years of age with a BMI greater than 24 kg/m2. 
We also estimated a -0.96% (95% CI: -1.44, 0.48%) reduction in 12-year cumulative 
incidence of CHD following a 5% reduction in WC down to a WC of 88 cm in adults 
under 65 years of age. We estimated that 9% and 16% of CHD events occurring in 
this study population over 12 years could have been prevented by a 5% shift in BMI 
and WC, respectively. 
The risk reduction in CHD was larger following a hypothetical 5% WC 
reduction compared to a hypothetical 5% BMI reduction, which may suggest a 
stronger metabolic impact of WC modifications on the associated risk of CHD. Other 
reasons for this difference to be considered are residual confounding if preclinical 
disease is present1, although we adjusted for baseline morbidity/chronic conditions 
related to weight change, and model misspecification. While correct model 
specification under the hypothetical reduction in adiposity cannot be demonstrated2, 
we saw no indications of model misspecification in reference to the natural course 
models.     
10.3 Strengths and weaknesses 
Several weaknesses of this study should be highlighted. To meet the 
assumptions built into the analytic model these analyses were limited to the initial 
three, consecutive re-examination visits of the ARIC cohort. As a result, the length of 
our follow-up is unlikely to fully capture the long term impact of adiposity at midlife on 
the risk of PAD and CHD during the life epochs when the incidence of PAD and 
CHD is highest. Since the use of WC as a measure of adiposity is reportedly not 
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accurate in individuals with a BMI over 40 kg/m2 3 we excluded participants at the 
upper and lower 1% of the baseline population distribution of WC, which was also 
done for the analysis of BMI. Our estimates are therefore not generalizable to the 
segment of the population that exceeds this BMI threshold value.  
Adiposity is a complex trait, influenced by factors ranging from behaviors to 
social norms, education, ethnicity, economic factors and food marketing practices, 
and reductions in adiposity may be achieved through various means. While targeted 
interventions at the population level can be desirable and feasible, such as the 
reduction of salt content in processed foods, single interventions on complex traits 
such as adiposity are likely to be less relevant for population-based policy. Further, 
different methods to change adiposity in populations may influence the risk of PAD 
and CHD through mechanisms that do not involve adiposity, even if they were to 
achieve the same value of BMI or WC. Single interventions involving adiposity 
reduction are thus sensitive to the treatment version irrelevance assumption, which 
states that the method by which adiposity reduction occurs should not affect the 
outcome4, that is, whether the reduction occurs due to dietary, exercise, or other 
lifestyle changes should not affect our results. In our data, this effect is identified 
through natural reductions (or increases) in BMI and WC, so our hypothetical 
intervention approximates what would occur if individuals were motivated to reduce 
adiposity through their own means, or structural or contextual changes occurred that 
affected the energy balance throughout the population.     
Strengths of our study derive from the estimation of the effect of a 
hypothetical reduction in adiposity on the incidence of PAD and CHD in a bi-racial 
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cohort of men and women, to our knowledge for the first time. We applied a 
hypothetical shift to the population distribution of adiposity at a threshold that was 
established to be near the clinical guidelines for excess adiposity, which for our 
population was at the 24th percentile of the baseline distribution of BMI and WC.  
10.4 Dissertation process 
In approaching the aims of this dissertation, we overcame challenges mostly 
related to the methodologic complexity and computational requirements of using the 
parametric g-formula. In approaching the methods for Aims 2 and 3, we learned that 
traditional regression methods would not allow for inclusion of time-varying 
confounders such as diabetes and hypertension in the estimation of these 
associations. Furthermore, diabetes and hypertension are time-varying covariates 
that are posited to lie on the causal pathway between BMI and the two specified 
CVD – PAD and CHD, and are in turn affected by previous BMI. To overcome the 
limitations of standard analytic methods and to allow for application of our 
hypothetical adiposity reduction at multiple time points, we chose to use the 
parametric g-formula5, an approach that combines parametric regression modeling 
to obtain conditional probabilities and Monte Carlo sampling to approximate 
standardization and to estimate measures of effect. Although the parametric g-
formula has been implemented to examine the effects of hypothetical shifts in the 
population distribution of various risk factors on conditions such as CHD6, diabetes7, 
cancer8, HIV9, and asthma10, such an approach has not been applied to our 
knowledge for adiposity and PAD. Furthermore, this approach has not been 
conducted in a bi-racial cohort nor has it been conducted using measures of 
adiposity other than BMI.  
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To implement the parametric g-formula, we collaborated with faculty (Drs. 
Cole and Westreich), a post-doctoral fellow (Alex Keil) and a student (Catherine 
Lesko) at the University of North Carolina (UNC) who focus on epidemiologic 
methods. No uniform way to run these estimations was available so the UNC Odum 
institute and others at UNC who focus on epidemiologic methods helped to write an 
efficient statistical program in SAS to run these analyses. The UNC Information 
Technology Services department created a state of the art virtual desktop 
environment with the computation requirements needed to run our analyses.   
10.5 Future directions 
Replication of these results in other populations is a desirable next step to 
assure the generalizability of the results emerging from this research. Analyses 
stratified by race also are warranted as the frequency of occurrence of PAD and 
CHD, like that of other cardiovascular diseases, is higher among African 
Americans11, whose cardiovascular risk profiles and burden of adverse health 
outcomes are higher than those of other race groups. There also is need for 
characterization of the effect of reducing mid-life adiposity on PAD and CHD with an 
extended follow-up time, and to older ages when PAD and CHD risk is highest. This 
work also warrants application to other cohorts with diversity to enrich the 
information base, especially in multi-ethnic cohorts where the distribution of adiposity 
may be different than what is observed in the ARIC cohort.  Declines in mortality and 
incidence of CHD have been reported over the last two decades12 and ongoing 
primary prevention of risk factors for CVD likely are required to continue the 
trajectory of these declines13. 
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If replicated, these results can inform research into the effects of dynamic 
population distributions of various measures of adiposity toward public health efforts 
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Proposed Specific Aims         
 Aim 1. Quantify the change in three specified cardio-metabolic factors 
associated with decrements in adiposity, of the kind achieved with lifestyle behavior 
modification programs, in the range of the temporal trends documented for young 
and middle-aged adults in the U.S.  Hypothesis: Effects of reduction in adiposity 
(BMI) on SBP, FPG and fasting LDL-C estimated in a meta-analysis of weight 
reduction interventions will be linear, without evidence of a threshold.  Methods: 
Effect measures from changes in adiposity metrics on three cardio-metabolic risk 
factors will be quantified individually and simultaneously from a meta-analysis of 
diet, physical activity and surgical weight loss interventions.     Aim 2. 
Estimate the individual and joint impact of decrements in adiposity on three cardio-
metabolic risk factors and apply these estimates to population-based samples of 
African Americans and whites from the ARIC cohort.  Hypothesis: (a) The effect of a 
reduction in adiposity on SBP, FPG and fasting LDL-C in a prospective, bi-racial 
observational cohort will be best fit as linear, without evidence of a threshold over 
the range of the adiposity distributions.  (b) Pre-specified reductions of small 
magnitude in adiposity informed by the literature will shift the cardio-metabolic profile 
of the population in an additive fashion, as predicted from the literature on weight 
reduction interventions and the empirical estimates from these cohorts.  Methods: 
Empirical effect measures of change in adiposity on three cardio-metabolic factors 
will be estimated from longitudinal data on African Americans and whites in the ARIC 
cohort and calibrated against the summary estimates from the meta-analysis of 
lifestyle modification programs.  Multivariate regression modeling will be employed to 
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examine individual and joint impacts of changes in BMI on the three cardio-
metabolic risk factors.   Aim 3. Estimate the change in longevity, disability and 
the incidence of diabetes and coronary heart disease (CHD) predicted from small 
changes in the population distribution of adiposity, in a sample of African Americans 
and whites.  Hypothesis: Small reductions in adiposity will be associated with 
detectable (beneficial) differences in years of life lost (YLL), years lived with disability 
(YLD), risk of diabetes, fatal and non-fatal CHD, and cerebrovascular disease 
predicted from the ARIC cohort data.  Methods: Population burden will be estimated 
as YLL, YLD, and its composite measure of disability adjusted life years (DALYs).  
Incidence rate differences and 95% confidence intervals (1) will be estimated for 
diabetes and CHD.  The population burden of disability, morbidity and premature 
death will be estimated directly for BMI and for the cardio-metabolic risk factors 
based on the change in cardio-metabolic factor predicted from the pre-specified 
change in adiposity metrics.    
The estimation of the health impact of small changes in adiposity shown to be 
feasible through lifestyle behavior modification in population-based cohorts of 
African Americans and whites will provide a sound empirical base for the planning of 
population intervention strategies directly relevant to the primary and secondary 
prevention of the conditions that most severely impact the burden of disease in U.S. 
adults. 
 
